ClinicalTrials.gg
CompletedNCT03823300Updated Jul 11, 2025Results posted

A Study to Evaluate the Efficacy and Safety of Faricimab in Participants With Neovascular Age-Related Macular Degeneration (LUCERNE)

A Phase 3 interventional study of Faricimab and Aflibercept in Wet Macular Degeneration, sponsored by Hoffmann-La Roche. Completed at 137 sites in 21 countries. Open to participants aged 50 Years and older. Per ClinicalTrials.gov, last updated 2025-07-11.

Sponsored by Hoffmann-La Roche · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
658
Allocation
Randomized
Ages
50 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 49 studies in Wet Macular Degeneration with a site in United States — 7 open to participants now, 14 under way, 7 of them phase 3. Wet Macular Degeneration · United States.

Enrollment
9th of 45
658 · median 91
Started
2019
with 9 others
Phase 3
13 of 49
1 open now
Registered
21st of 49
by date
Lead sponsor
2 of 49
Hoffmann-La Roche

Among the 49 studies in Wet Macular Degeneration with a site in United States, this one is the 9th largest by enrollment of the 45 interventional ones that give a count, is one of 10 that started in 2019, is one of 13 in phase 3, and was the 21st registered.

Wet Macular Degeneration

93 studies on the registry are indexed under Wet Macular Degeneration; 10 are open to participants now.

Browse Wet Macular Degeneration studies →

Open to participants now

7 of the 49 studies in Wet Macular Degeneration with a site in United States are open now. Recruiting first, the newest first:

2 more — sign in →

All 7 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 8 Wet Macular Degeneration studies recruiting now, 5 set no upper age limit and none stop at 75 or younger; none take children under 18; none take healthy volunteers.

This study: 50 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 49 studies in Wet Macular Degeneration with a site in United States, or all of them as a file.
02

Study summary

This study will evaluate the efficacy, safety, durability, and pharmacokinetics of faricimab administered at intervals as specified in the protocol, compared with aflibercept once every 8 weeks (Q8W), in participants with neovascular age-related macular degeneration (nAMD).

03

Conditions studied

  • Wet Macular Degeneration

Keywords

  • AMD
  • nAMD
  • neovascular age-related macular degeneration
  • choroidal neovascularization secondary to age-related macular degeneration
04

Who can participate

Ages eligible
50 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Treatment-naïve choroidal neovascularization (CNV) secondary to age-related macular degeneration (nAMD) in the study eye
  • Ability to comply with the study protocol, in the investigator's judgment
  • For women of : agreement to remain abstinent (refrain from heterosexual intercourse) or use acceptable measures that result in failure rate \<1% per year during the treatment period and for at least 3 months after the final dose of study treatment
  • Other protocol-specified inclusion criteria may apply

Exclusion criteria

Exclusion Criteria:

  • Uncontrolled blood pressure, defined as systolic blood pressure >180 millimeters of mercury (mmHg) and/or diastolic blood pressure >100 mmHg while a patient is at rest on Day 1
  • Pregnancy or breastfeeding, or intention to become pregnant during the study
  • CNV due to causes other than AMD in the study eye
  • Any history of macular pathology unrelated to AMD affecting vision or contributing to the presence of intraretinal or subretinal fluid in the study eye
  • Any concurrent intraocular condition in the study eye that, in the opinion of the investigator, could either reduce the potential for visual improvement or require medical or surgical intervention during the study
  • Uncontrolled glaucoma in the study eye
  • Any prior or concomitant treatment for CNV or vitreomacular-interface abnormalities in the study eye
  • Prior IVT administration of faricimab in either eye
  • History of idiopathic or -associated uveitis in either eye
  • Active ocular inflammation or suspected or active ocular or periocular infection in either eye
  • Other protocol-specified exclusion criteria may apply
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Investigator, Outcomes assessor)
Enrollment
658 participants (actual)

Study arms

  • Experimental
    Arm A: Faricimab

    Drug: Faricimab · Procedure: Sham Procedure

  • Active comparator
    Arm B: Aflibercept

    Drug: Aflibercept · Procedure: Sham Procedure

Interventions

  • Faricimab will be administered by intravitreal injection into the study eye at intervals as specified in the study protocol.

    Also known as: VABYSMO™, RO6867461, RG7716

  • Aflibercept will be administered by intravitreal injection into the study eye once every 4 weeks for 3 consecutive months, followed by once every 8 weeks (Q8W).

    Also known as: Eylea

  • ProcedureSham Procedure

    The sham is a procedure that mimics an intravitreal injection, but involves the blunt end of an empty syringe (without a needle) being pressed against the anesthetized eye. It will be administered to participants in both treatment arms at applicable visits to maintain masking.

06

What researchers measure

Primary outcomes

  1. Change From Baseline in BCVA in the Study Eye Averaged Over Weeks 40, 44, and 48

    Best Corrected Visual Acuity (BCVA) was measured on the Early Treatment Diabetic Retinopathy Study (ETDRS) chart at a starting distance of 4 meters. The BCVA letter score ranges from 0 to 100 (best score), and a gain in BCVA from baseline indicates an improvement in visual acuity. The Mixed Model of Repeated Measures (MMRM) analysis adjusted for treatment arm, visit, visit-by-treatment arm interaction, baseline BCVA (continuous), baseline BCVA (≥74, 73-55, and ≤54 letters), baseline LLD (\<33 and ≥33 letters), and region (U.S. and Canada, Asia, and rest of the world). An unstructured covariance structure was used. Treatment policy strategy (i.e., all observed values used) and hypothetical strategy (i.e., all values censored after occurrence of the intercurrent event) were applied to non-COVID-19 related and COVID-19 related intercurrent events, respectively. Missing data were implicitly imputed by MMRM. Invalid BCVA values were excluded from analysis. 95% CI is a rounding of 95.03% CI.

    Time frame: From Baseline through Week 48

Secondary outcomes

  1. Change From Baseline in BCVA in the Study Eye Averaged Over Weeks 52, 56, and 60

    Best Corrected Visual Acuity (BCVA) was measured on the Early Treatment Diabetic Retinopathy Study (ETDRS) chart at a starting distance of 4 meters. The BCVA letter score ranges from 0 to 100 (best score), and a gain in BCVA from baseline indicates an improvement in visual acuity. The Mixed Model of Repeated Measures (MMRM) analysis adjusted for treatment arm, visit, visit-by-treatment arm interaction, baseline BCVA (continuous), baseline BCVA (≥74, 73-55, and ≤54 letters), baseline LLD (\<33 and ≥33 letters), and region (U.S. and Canada, Asia, and rest of the world). An unstructured covariance structure was used. Treatment policy strategy (i.e., all observed values used) and hypothetical strategy (i.e., all values censored after occurrence of the intercurrent event) were applied to non-COVID-19 related and COVID-19 related intercurrent events, respectively. Missing data were implicitly imputed by MMRM. Invalid BCVA values were excluded from analysis. 95% CI is a rounding of 95.03% CI.

    Time frame: From Baseline through Week 60

  2. Change From Baseline in BCVA in the Study Eye Over Time

    Best Corrected Visual Acuity (BCVA) was measured on the Early Treatment Diabetic Retinopathy Study (ETDRS) chart at a starting distance of 4 meters. The BCVA letter score ranges from 0 to 100 (best score), and a gain in BCVA from baseline indicates an improvement in visual acuity. The Mixed Model of Repeated Measures (MMRM) analysis adjusted for treatment arm, visit, visit-by-treatment arm interaction, baseline BCVA (continuous), baseline BCVA (≥74, 73-55, and ≤54 letters), baseline LLD (\<33 and ≥33 letters), and region (U.S. and Canada, Asia, and rest of the world). An unstructured covariance structure was used. Treatment policy strategy (i.e., all observed values used) and hypothetical strategy (i.e., all values censored after occurrence of the intercurrent event) were applied to non-COVID-19 related and COVID-19 related intercurrent events, respectively. Missing data were implicitly imputed by MMRM. Invalid BCVA values were excluded from analysis. 95% CI is a rounding of 95.03% CI.

    Time frame: Baseline, Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52, 56, 60, 64, 68, 72, 76, 80, 84, 88, 92, 96, 100, 104, 108, and 112

  3. Percentage of Participants Gaining Greater Than or Equal to (≥)15, ≥10, ≥5, or ≥0 Letters From the Baseline BCVA in the Study Eye Averaged Over Weeks 40, 44, and 48

    BCVA was measured on the ETDRS chart at a starting distance of 4 meters. The BCVA letter score ranges from 0 to 100 (best score), and a gain in BCVA from baseline indicates an improvement in visual acuity. For each participant, an average BCVA value was calculated across the three visits, and this averaged value was used to determine if the endpoint was met. The results were summarized as the percentage of participants per treatment arm who met the endpoint. The weighted percentage of participants was based on the Cochran-Mantel Haenszel (CMH) weights stratified by baseline BCVA (≥74 letters, 73-55 letters, and ≤54 letters), baseline LLD (≥33 letters and \<33 letters), and region (U.S. and Canada vs. rest of the world). Treatment policy strategy and hypothetical strategy were applied to non-COVID-19 related and COVID-19 related intercurrent events, respectively. Missing data were not imputed. Invalid BCVA values were excluded. 95% confidence interval (CI) is a rounding of 95.03% CI.

    Time frame: Baseline, average of Weeks 40, 44, and 48

  4. Percentage of Participants Gaining ≥15 Letters From the Baseline BCVA in the Study Eye Averaged Over Weeks 52, 56, and 60

    BCVA was measured on the ETDRS chart at a starting distance of 4 meters. The BCVA letter score ranges from 0 to 100 (best score), and a gain in BCVA from baseline indicates an improvement in visual acuity. For each participant, an average BCVA value was calculated across the three visits, and this averaged value was used to determine if the endpoint was met. The results were summarized as the percentage of participants per treatment arm who met the endpoint. The weighted percentage of participants was based on the Cochran-Mantel Haenszel (CMH) weights stratified by baseline BCVA (≥74 letters, 73-55 letters, and ≤54 letters), baseline LLD (≥33 letters and \<33 letters), and region (U.S. and Canada vs. rest of the world). Treatment policy strategy and hypothetical strategy were applied to non-COVID-19 related and COVID-19 related intercurrent events, respectively. Missing data were not imputed. Invalid BCVA values were excluded. 95% confidence interval (CI) is a rounding of 95.03% CI.

    Time frame: Baseline, average of Weeks 52, 56, and 60

  5. Percentage of Participants Gaining ≥15 Letters From the Baseline BCVA in the Study Eye Over Time

    Best Corrected Visual Acuity (BCVA) was measured on the Early Treatment Diabetic Retinopathy Study (ETDRS) chart at a starting distance of 4 meters. The BCVA letter score ranges from 0 to 100 (best score), and a gain in BCVA letter score from baseline indicates an improvement in visual acuity. The weighted percentage of participants was based on the Cochran-Mantel Haenszel (CMH) weights stratified by baseline BCVA (≥74 letters, 73-55 letters, and ≤54 letters), baseline LLD (≥33 letters and \<33 letters), and region (U.S. and Canada vs. rest of the world; Asia and rest of the world were combined). Treatment policy strategy (i.e., all observed values used) and hypothetical strategy (i.e., all values censored after the occurrence of the intercurrent event) were applied to non-COVID-19 related and COVID-19 related intercurrent events, respectively. Missing data were not imputed. Invalid BCVA values were excluded from analysis. 95% confidence interval (CI) is a rounding of 95.03% CI.

    Time frame: Baseline, Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52, 56, 60, 64, 68, 72, 76, 80, 84, 88, 92, 96, 100, 104, 108, and 112

  6. Percentage of Participants Gaining ≥10 Letters From the Baseline BCVA in the Study Eye Over Time

    Best Corrected Visual Acuity (BCVA) was measured on the Early Treatment Diabetic Retinopathy Study (ETDRS) chart at a starting distance of 4 meters. The BCVA letter score ranges from 0 to 100 (best score), and a gain in BCVA letter score from baseline indicates an improvement in visual acuity. The weighted percentage of participants was based on the Cochran-Mantel Haenszel (CMH) weights stratified by baseline BCVA (≥74 letters, 73-55 letters, and ≤54 letters), baseline LLD (≥33 letters and \<33 letters), and region (U.S. and Canada vs. rest of the world; Asia and rest of the world were combined). Treatment policy strategy (i.e., all observed values used) and hypothetical strategy (i.e., all values censored after the occurrence of the intercurrent event) were applied to non-COVID-19 related and COVID-19 related intercurrent events, respectively. Missing data were not imputed. Invalid BCVA values were excluded from analysis. 95% confidence interval (CI) is a rounding of 95.03% CI.

    Time frame: Baseline, Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52, 56, 60, 64, 68, 72, 76, 80, 84, 88, 92, 96, 100, 104, 108, and 112

  7. Percentage of Participants Gaining ≥5 Letters From the Baseline BCVA in the Study Eye Over Time

    Best Corrected Visual Acuity (BCVA) was measured on the Early Treatment Diabetic Retinopathy Study (ETDRS) chart at a starting distance of 4 meters. The BCVA letter score ranges from 0 to 100 (best score), and a gain in BCVA letter score from baseline indicates an improvement in visual acuity. The weighted percentage of participants was based on the Cochran-Mantel Haenszel (CMH) weights stratified by baseline BCVA (≥74 letters, 73-55 letters, and ≤54 letters), baseline LLD (≥33 letters and \<33 letters), and region (U.S. and Canada vs. rest of the world; Asia and rest of the world were combined). Treatment policy strategy (i.e., all observed values used) and hypothetical strategy (i.e., all values censored after the occurrence of the intercurrent event) were applied to non-COVID-19 related and COVID-19 related intercurrent events, respectively. Missing data were not imputed. Invalid BCVA values were excluded from analysis. 95% confidence interval (CI) is a rounding of 95.03% CI.

    Time frame: Baseline, Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52, 56, 60, 64, 68, 72, 76, 80, 84, 88, 92, 96, 100, 104, 108, and 112

  8. Percentage of Participants Gaining ≥0 Letters From the Baseline BCVA in the Study Eye Over Time

    Best Corrected Visual Acuity (BCVA) was measured on the Early Treatment Diabetic Retinopathy Study (ETDRS) chart at a starting distance of 4 meters. The BCVA letter score ranges from 0 to 100 (best score), and a gain in BCVA letter score from baseline indicates an improvement in visual acuity. The weighted percentage of participants was based on the Cochran-Mantel Haenszel (CMH) weights stratified by baseline BCVA (≥74 letters, 73-55 letters, and ≤54 letters), baseline LLD (≥33 letters and \<33 letters), and region (U.S. and Canada vs. rest of the world; Asia and rest of the world were combined). Treatment policy strategy (i.e., all observed values used) and hypothetical strategy (i.e., all values censored after the occurrence of the intercurrent event) were applied to non-COVID-19 related and COVID-19 related intercurrent events, respectively. Missing data were not imputed. Invalid BCVA values were excluded from analysis. 95% confidence interval (CI) is a rounding of 95.03% CI.

    Time frame: Baseline, Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52, 56, 60, 64, 68, 72, 76, 80, 84, 88, 92, 96, 100, 104, 108, and 112

  9. Percentage of Participants Avoiding a Loss of ≥15, ≥10, or ≥5 Letters From the Baseline BCVA in the Study Eye Averaged Over Weeks 40, 44, and 48

    Best Corrected Visual Acuity (BCVA) was measured on the Early Treatment Diabetic Retinopathy Study (ETDRS) chart at a starting distance of 4 meters. For each participant, an average BCVA value was calculated across the three visits, and this averaged value was then used to determine if the endpoint was met. The results were summarized as the percentage of participants per treatment arm who met the endpoint. The weighted percentage of participants was based on the Cochran-Mantel Haenszel (CMH) weights stratified by baseline BCVA (≥74 letters, 73-55 letters, and ≤54 letters), baseline LLD (≥33 letters and \<33 letters), and region (U.S. and Canada vs. rest of the world). Treatment policy strategy and hypothetical strategy were applied to non-COVID-19 related and COVID-19 related intercurrent events, respectively. Missing data were not imputed. Invalid BCVA values were excluded. 95% confidence interval (CI) is a rounding of 95.03% CI.

    Time frame: Baseline, average of Weeks 40, 44, and 48

  10. Percentage of Participants Avoiding a Loss of ≥15 Letters From the Baseline BCVA in the Study Eye Averaged Over Weeks 52, 56, and 60

    Best Corrected Visual Acuity (BCVA) was measured on the Early Treatment Diabetic Retinopathy Study (ETDRS) chart at a starting distance of 4 meters. For each participant, an average BCVA value was calculated across the three visits, and this averaged value was then used to determine if the endpoint was met. The results were summarized as the percentage of participants per treatment arm who met the endpoint. The weighted percentage of participants was based on the Cochran-Mantel Haenszel (CMH) weights stratified by baseline BCVA (≥74 letters, 73-55 letters, and ≤54 letters), baseline LLD (≥33 letters and \<33 letters), and region (U.S. and Canada vs. rest of the world). Treatment policy strategy and hypothetical strategy were applied to non-COVID-19 related and COVID-19 related intercurrent events, respectively. Missing data were not imputed. Invalid BCVA values were excluded. 95% confidence interval (CI) is a rounding of 95.03% CI.

    Time frame: Baseline, average of Weeks 52, 56, and 60

  11. Percentage of Participants Avoiding a Loss of ≥15 Letters From the Baseline BCVA in the Study Eye Over Time

    Best Corrected Visual Acuity (BCVA) was measured on the Early Treatment Diabetic Retinopathy Study (ETDRS) chart at a starting distance of 4 meters. The weighted percentage of participants avoiding a loss of letters in BCVA from baseline was based on the Cochran-Mantel Haenszel (CMH) weights stratified by baseline BCVA (≥74 letters, 73-55 letters, and ≤54 letters), baseline LLD (≥33 letters and \<33 letters), and region (U.S. and Canada vs. rest of the world; Asia and rest of the world were combined). Treatment policy strategy (i.e., all observed values used) and hypothetical strategy (i.e., all values censored after the occurrence of the intercurrent event) were applied to non-COVID-19 related and COVID-19 related intercurrent events, respectively. Missing data were not imputed. Invalid BCVA values were excluded from analysis. 95% confidence interval (CI) is a rounding of 95.03% CI.

    Time frame: Baseline, Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52, 56, 60, 64, 68, 72, 76, 80, 84, 88, 92, 96, 100, 104, 108, and 112

  12. Percentage of Participants Avoiding a Loss of ≥10 Letters From the Baseline BCVA in the Study Eye Over Time

    Best Corrected Visual Acuity (BCVA) was measured on the Early Treatment Diabetic Retinopathy Study (ETDRS) chart at a starting distance of 4 meters. The weighted percentage of participants avoiding a loss of letters in BCVA from baseline was based on the Cochran-Mantel Haenszel (CMH) weights stratified by baseline BCVA (≥74 letters, 73-55 letters, and ≤54 letters), baseline LLD (≥33 letters and \<33 letters), and region (U.S. and Canada vs. rest of the world; Asia and rest of the world were combined). Treatment policy strategy (i.e., all observed values used) and hypothetical strategy (i.e., all values censored after the occurrence of the intercurrent event) were applied to non-COVID-19 related and COVID-19 related intercurrent events, respectively. Missing data were not imputed. Invalid BCVA values were excluded from analysis. 95% confidence interval (CI) is a rounding of 95.03% CI.

    Time frame: Baseline, Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52, 56, 60, 64, 68, 72, 76, 80, 84, 88, 92, 96, 100, 104, 108, and 112

  13. Percentage of Participants Avoiding a Loss of ≥5 Letters From the Baseline BCVA in the Study Eye Over Time

    Best Corrected Visual Acuity (BCVA) was measured on the Early Treatment Diabetic Retinopathy Study (ETDRS) chart at a starting distance of 4 meters. The weighted percentage of participants avoiding a loss of letters in BCVA from baseline was based on the Cochran-Mantel Haenszel (CMH) weights stratified by baseline BCVA (≥74 letters, 73-55 letters, and ≤54 letters), baseline LLD (≥33 letters and \<33 letters), and region (U.S. and Canada vs. rest of the world; Asia and rest of the world were combined). Treatment policy strategy (i.e., all observed values used) and hypothetical strategy (i.e., all values censored after the occurrence of the intercurrent event) were applied to non-COVID-19 related and COVID-19 related intercurrent events, respectively. Missing data were not imputed. Invalid BCVA values were excluded from analysis. 95% confidence interval (CI) is a rounding of 95.03% CI.

    Time frame: Baseline, Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52, 56, 60, 64, 68, 72, 76, 80, 84, 88, 92, 96, 100, 104, 108, and 112

  14. Percentage of Participants Gaining ≥15 Letters From the Baseline BCVA or Achieving BCVA Snellen Equivalent of 20/20 or Better (BCVA ≥84 Letters) in the Study Eye Averaged Over Weeks 40, 44, and 48

    BCVA was measured on the ETDRS chart at a starting distance of 4 meters. The BCVA letter score ranges from 0 to 100 (best score), and a gain in BCVA from baseline indicates an improvement in visual acuity. For each participant, an average BCVA value was calculated across the three visits, and this averaged value was used to determine if the endpoint was met. The results were summarized as the percentage of participants per treatment arm who met the endpoint. The weighted percentage of participants was based on the Cochran-Mantel Haenszel (CMH) weights stratified by baseline BCVA (≥74 letters, 73-55 letters, and ≤54 letters), baseline LLD (≥33 letters and \<33 letters), and region (U.S. and Canada vs. rest of the world). Treatment policy strategy and hypothetical strategy were applied to non-COVID-19 related and COVID-19 related intercurrent events, respectively. Missing data were not imputed. Invalid BCVA values were excluded. 95% confidence interval (CI) is a rounding of 95.03% CI.

    Time frame: Baseline, average of Weeks 40, 44, and 48

  15. Percentage of Participants Gaining ≥15 Letters From the Baseline BCVA or Achieving BCVA Snellen Equivalent of 20/20 or Better (BCVA ≥84 Letters) in the Study Eye Over Time

    Best Corrected Visual Acuity (BCVA) was measured on the Early Treatment Diabetic Retinopathy Study (ETDRS) chart at a starting distance of 4 meters. The BCVA letter score ranges from 0 to 100 (best score), and a gain in BCVA letter score from baseline indicates an improvement in visual acuity. The weighted percentage of participants was based on the Cochran-Mantel Haenszel (CMH) weights stratified by baseline BCVA (≥74 letters, 73-55 letters, and ≤54 letters), baseline LLD (≥33 letters and \<33 letters), and region (U.S. and Canada vs. rest of the world; Asia and rest of the world were combined). Treatment policy strategy (i.e., all observed values used) and hypothetical strategy (i.e., all values censored after the occurrence of the intercurrent event) were applied to non-COVID-19 related and COVID-19 related intercurrent events, respectively. Missing data were not imputed. Invalid BCVA values were excluded from analysis. 95% confidence interval (CI) is a rounding of 95.03% CI.

    Time frame: Baseline, Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52, 56, 60, 64, 68, 72, 76, 80, 84, 88, 92, 96, 100, 104, 108, and 112

  16. Percentage of Participants With BCVA Snellen Equivalent of 20/40 or Better (BCVA ≥69 Letters) in the Study Eye Averaged Over Weeks 40, 44, and 48

    BCVA was measured on the ETDRS chart at a starting distance of 4 meters. The BCVA letter score ranges from 0 to 100 (best score), and a gain in BCVA from baseline indicates an improvement in visual acuity. For each participant, an average BCVA value was calculated across the three visits, and this averaged value was used to determine if the endpoint was met. The results were summarized as the percentage of participants per treatment arm who met the endpoint. The weighted estimates of the percentage of participants were based on the Cochran-Mantel Haenszel (CMH) weights stratified by baseline BCVA (\<69 letters vs. ≥69 letters), baseline LLD (≥33 letters and \<33 letters), and region (U.S. and Canada vs. rest of the world). Treatment policy strategy and hypothetical strategy were applied to non-COVID-19 related and COVID-19 related intercurrent events, respectively. Missing data were not imputed. Invalid BCVA values were excluded. 95% confidence interval (CI) is a rounding of 95.03% CI.

    Time frame: Baseline, average of Weeks 40, 44, and 48

  17. Percentage of Participants With BCVA Snellen Equivalent of 20/40 or Better (BCVA ≥69 Letters) in the Study Eye Over Time

    Best Corrected Visual Acuity (BCVA) was measured on the Early Treatment Diabetic Retinopathy Study (ETDRS) chart at a starting distance of 4 meters. The BCVA letter score ranges from 0 to 100 (best score), and a gain in BCVA letter score from baseline indicates an improvement in visual acuity. The weighted percentage of participants was based on the Cochran-Mantel Haenszel (CMH) weights stratified by baseline BCVA (\<69 letters vs. ≥69 letters), baseline LLD (≥33 letters and \<33 letters), and region (U.S. and Canada vs. rest of the world; Asia and rest of the world were combined). Treatment policy strategy (i.e., all observed values used) and hypothetical strategy (i.e., all values censored after the occurrence of the intercurrent event) were applied to non-COVID-19 related and COVID-19 related intercurrent events, respectively. Missing data were not imputed. Invalid BCVA values were excluded from analysis. 95% confidence interval (CI) is a rounding of 95.03% CI.

    Time frame: Baseline, Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52, 56, 60, 64, 68, 72, 76, 80, 84, 88, 92, 96, 100, 104, 108, and 112

  18. Percentage of Participants With BCVA Snellen Equivalent of 20/200 or Worse (BCVA ≤38 Letters) in the Study Eye Averaged Over Weeks 40, 44, and 48

    BCVA was measured on the ETDRS chart at a starting distance of 4 meters. The BCVA letter score ranges from 0 to 100 (best score), and a gain in BCVA from baseline indicates an improvement in visual acuity. For each participant, an average BCVA value was calculated across the three visits, and this averaged value was used to determine if the endpoint was met. The results were summarized as the percentage of participants per treatment arm who met the endpoint. The weighted percentage of participants was based on the Cochran-Mantel Haenszel (CMH) weights stratified by baseline BCVA (≥74 letters, 73-55 letters, and ≤54 letters), baseline LLD (≥33 letters and \<33 letters), and region (U.S. and Canada vs. rest of the world). Treatment policy strategy and hypothetical strategy were applied to non-COVID-19 related and COVID-19 related intercurrent events, respectively. Missing data were not imputed. Invalid BCVA values were excluded. 95% confidence interval (CI) is a rounding of 95.03% CI.

    Time frame: Baseline, average of Weeks 40, 44, and 48

  19. Percentage of Participants With BCVA Snellen Equivalent of 20/200 or Worse (BCVA ≤38 Letters) in the Study Eye Over Time

    Best Corrected Visual Acuity (BCVA) was measured on the Early Treatment Diabetic Retinopathy Study (ETDRS) chart at a starting distance of 4 meters. The BCVA letter score ranges from 0 to 100 (best score), and a gain in BCVA letter score from baseline indicates an improvement in visual acuity. The weighted percentage of participants was based on the Cochran-Mantel Haenszel (CMH) weights stratified by baseline BCVA (≥74 letters, 73-55 letters, and ≤54 letters), baseline LLD (≥33 letters and \<33 letters), and region (U.S. and Canada vs. rest of the world; Asia and rest of the world were combined). Treatment policy strategy (i.e., all observed values used) and hypothetical strategy (i.e., all values censored after the occurrence of the intercurrent event) were applied to non-COVID-19 related and COVID-19 related intercurrent events, respectively. Missing data were not imputed. Invalid BCVA values were excluded from analysis. 95% confidence interval (CI) is a rounding of 95.03% CI.

    Time frame: Baseline, Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52, 56, 60, 64, 68, 72, 76, 80, 84, 88, 92, 96, 100, 104, 108, and 112

  20. Percentage of Participants in the Faricimab Arm on Once Every 8-Weeks, 12-Weeks, or 16-Weeks Treatment Intervals Among Those Completing Week 48

    Percentages are based on the number of participants randomized to the faricimab arm who have not discontinued the study at Week 48. The treatment interval at a given visit is defined as the treatment interval decision followed at that visit. The 95% confidence interval (CI) is a rounding of 95.03% CI.

    Time frame: Week 48

  21. Percentage of Participants in the Faricimab Arm on Once Every 8-Weeks, 12-Weeks, or 16-Weeks Treatment Intervals Among Those Completing Week 60

    Percentages are based on the number of participants randomized to the faricimab arm who have not discontinued the study at Week 60. The treatment interval at a given visit is defined as the treatment interval decision followed at that visit. The 95% confidence interval (CI) is a rounding of 95.03% CI.

    Time frame: Week 60

  22. Percentage of Participants in the Faricimab Arm on Once Every 8-Weeks, 12-Weeks, or 16-Weeks Treatment Intervals Among Those Completing Week 112

    Percentages are based on the number of participants randomized to the faricimab arm who have not discontinued the study at Week 112. Treatment interval at a given visit is defined as the treatment interval decision followed at that visit. Treatment interval at Week 112 is calculated using data recorded at Week 108. The 95% confidence interval (CI) is a rounding of 95.03% CI.

    Time frame: Weeks 108 and 112

  23. Number of Study Drug Injections Received in the Study Eye Through Week 48

    Time frame: From Baseline through Week 48

  24. Number of Study Drug Injections Received in the Study Eye Through Week 60

    Time frame: From Baseline through Week 60

  25. Number of Study Drug Injections Received in the Study Eye Through Week 108

    Time frame: From Baseline through Week 108

  26. Change From Baseline in Central Subfield Thickness in the Study Eye Averaged Over Weeks 40, 44, and 48

    Central subfield thickness (CST) was defined as the distance between the internal limiting membrane (ILM) and the retinal pigment epithelium (RPE) using optical coherence tomography (OCT), as assessed by the central reading center. For the Mixed Model of Repeated Measures (MMRM) analysis, the model adjusted for treatment group, visit, visit-by-treatment group iteraction, baseline CST (continuous), baseline BCVA (≥74 letters, 73-55 letters, and ≤54 letters), baseline LLD (\<33 letters and ≥33 letters), and region (U.S. and Canada, Asia, and the rest of the world). An unstructured covariance structure was used. Treatment policy strategy (i.e., all observed values used) and hypothetical strategy (i.e., all values censored after the occurrence of the intercurrent event) were applied to non-COVID-19 related and COVID-19 related intercurrent events, respectively. Missing data were implicitly imputed by MMRM. 95% confidence interval (CI) is a rounding of 95.03% CI.

    Time frame: From Baseline through Week 48

  27. Change From Baseline in Central Subfield Thickness in the Study Eye Averaged Over Weeks 52, 56, and 60

    Central subfield thickness (CST) was defined as the distance between the internal limiting membrane (ILM) and the retinal pigment epithelium (RPE) using optical coherence tomography (OCT), as assessed by the central reading center. For the Mixed Model of Repeated Measures (MMRM) analysis, the model adjusted for treatment group, visit, visit-by-treatment group interaction, baseline CST (continuous), baseline BCVA (≥74 letters, 73-55 letters, and ≤54 letters), baseline LLD (\<33 letters and ≥33 letters), and region (U.S. and Canada, Asia, and the rest of the world). An unstructured covariance structure was used. Treatment policy strategy (i.e., all observed values used) and hypothetical strategy (i.e., all values censored after the occurrence of the intercurrent event) were applied to non-COVID-19 related and COVID-19 related intercurrent events, respectively. Missing data were implicitly imputed by MMRM. 95% confidence interval (CI) is a rounding of 95.03% CI.

    Time frame: From Baseline through Week 60

  28. Change From Baseline in Central Subfield Thickness in the Study Eye Over Time

    Central subfield thickness (CST) was defined as the distance between the internal limiting membrane (ILM) and the retinal pigment epithelium (RPE) using optical coherence tomography (OCT), as assessed by the central reading center. For the Mixed Model of Repeated Measures (MMRM) analysis, the model adjusted for treatment group, visit, visit-by-treatment group interaction, baseline CST (continuous), baseline BCVA (≥74 letters, 73-55 letters, and ≤54 letters), baseline LLD (\<33 letters and ≥33 letters), and region (U.S. and Canada, Asia, and the rest of the world). An unstructured covariance structure was used. Treatment policy strategy (i.e., all observed values used) and hypothetical strategy (i.e., all values censored after the occurrence of the intercurrent event) were applied to non-COVID-19 related and COVID-19 related intercurrent events, respectively. Missing data were implicitly imputed by MMRM. 95% confidence interval (CI) is a rounding of 95.03% CI.

    Time frame: Baseline, Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52, 56, 60, 64, 68, 72, 76, 80, 84, 88, 92, 96, 100, 104, 108, and 112

  29. Percentage of Participants With Absence of Intraretinal Fluid in the Study Eye Over Time

    Intraretinal fluid was measured using optical coherence tomography (OCT) in the central subfield (center 1 millimetre \[mm\]). The weighted estimates of the percentage of participants with absence of intraretinal fluid were based on the Cochran-Mantel Haenszel (CMH) weights stratified by baseline BCVA (≥74 letters, 73-55 letters, and ≤54 letters), baseline LLD (≥33 letters and \<33 letters), and region (U.S. and Canada vs. rest of the world). Asia and rest of the world regions were combined due to a small number of enrolled participants. Treatment policy strategy (i.e., all observed values used) and hypothetical strategy (i.e., all values censored after the occurrence of the intercurrent event) were applied to non-COVID-19 related and COVID-19 related intercurrent events, respectively. Missing data were not imputed. 95% confidence interval (CI) is a rounding of 95.03% CI.

    Time frame: Baseline, Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52, 56, 60, 104, 108, and 112

  30. Percentage of Participants With Absence of Subretinal Fluid in the Study Eye Over Time

    Subretinal fluid was measured using optical coherence tomography (OCT) in the central subfield (center 1 mm). The weighted estimates of the percentage of participants with absence of subretinal fluid were based on the Cochran-Mantel Haenszel (CMH) weights stratified by baseline BCVA (≥74 letters, 73-55 letters, and ≤54 letters), baseline LLD (≥33 letters and \<33 letters), and region (U.S. and Canada vs. rest of the world). Asia and rest of the world regions were combined due to a small number of enrolled participants. Treatment policy strategy (i.e., all observed values used) and hypothetical strategy (i.e., all values censored after the occurrence of the intercurrent event) were applied to non-COVID-19 related and COVID-19 related intercurrent events, respectively. Missing data were not imputed. 95% confidence interval (CI) is a rounding of 95.03% CI.

    Time frame: Baseline, Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52, 56, 60, 104, 108, and 112

  31. Percentage of Participants With Absence of Intraretinal Fluid and Subretinal Fluid in the Study Eye Over Time

    Intraretinal fluid and subretinal fluid were measured using optical coherence tomography (OCT) in the central subfield (center 1 mm). The weighted estimates of the percentage of participants with absence of intraretinal and subretinal fluid were based on the Cochran-Mantel Haenszel (CMH) weights stratified by baseline BCVA (≥74 letters, 73-55 letters, and ≤54 letters), baseline LLD (≥33 letters and \<33 letters), and region (U.S. and Canada vs. rest of the world). Asia and rest of the world regions were combined due to a small number of enrolled participants. Treatment policy strategy (i.e., all observed values used) and hypothetical strategy (i.e., all values censored after the occurrence of the intercurrent event) were applied to non-COVID-19 related and COVID-19 related intercurrent events, respectively. Missing data were not imputed. 95% confidence interval (CI) is a rounding of 95.03% CI.

    Time frame: Baseline, Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52, 56, 60, 104, 108, and 112

  32. Percentage of Participants With Absence of Pigment Epithelial Detachment in the Study Eye Over Time

    Pigment epithelial detachment was measured using optical coherence tomography (OCT) in the central subfield (center 1 mm). The weighted estimates of the percentage of participants with absence of pigment epithelial detachment were based on the Cochran-Mantel Haenszel (CMH) weights stratified by baseline BCVA (≥74 letters, 73-55 letters, and ≤54 letters), baseline LLD (≥33 letters and \<33 letters), and region (U.S. and Canada vs. rest of the world). Asia and rest of the world regions were combined due to a small number of enrolled participants. Treatment policy strategy (i.e., all observed values used) and hypothetical strategy (i.e., all values censored after the occurrence of the intercurrent event) were applied to non-COVID-19 related and COVID-19 related intercurrent events, respectively. Missing data were not imputed. 95% confidence interval (CI) is a rounding of 95.03% CI.

    Time frame: Baseline, Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52, 56, 60, 104, 108, and 112

  33. Percentage of Participants With Absence of Intraretinal Cysts in the Study Eye Over Time

    Time frame: Up to 112 weeks

  34. Change From Baseline in Total Area of Choroidal Neovascularization Lesion in the Study Eye at Week 48

    The total area of the choroidal neovascularization lesion in the study eye was evaluated by a central reading center using fundus fluorescein angiography (FFA). Assessments were censored following COVID-19 related intercurrent events. Baseline was defined as the last available measurement obtained on or prior to randomization.

    Time frame: Baseline and Week 48

  35. Change From Baseline in Total Area of Choroidal Neovascularization Lesion in the Study Eye at Week 112

    The total area of the choroidal neovascularization lesion in the study eye was evaluated by a central reading center using fundus fluorescein angiography (FFA). Assessments were censored following COVID-19 related intercurrent events. Baseline was defined as the last available measurement obtained on or prior to randomization.

    Time frame: Baseline and Week 112

  36. Change From Baseline in Total Area of Choroidal Neovascularization Leakage in the Study Eye at Week 48

    The total area of choroidal neovascularization leakage in the study eye was evaluated by a central reading center using fundus fluorescein angiography (FFA). Assessments were censored following COVID-19 related intercurrent events. Baseline was defined as the last available measurement obtained on or prior to randomization.

    Time frame: Baseline and Week 48

  37. Change From Baseline in Total Area of Choroidal Neovascularization Leakage in the Study Eye at Week 112

    The total area of choroidal neovascularization leakage in the study eye was evaluated by a central reading center using fundus fluorescein angiography (FFA). Assessments were censored following COVID-19 related intercurrent events. Baseline was defined as the last available measurement obtained on or prior to randomization.

    Time frame: Baseline and Week 112

  38. Percentage of Participants With at Least One Adverse Event

    This analysis of adverse events (AEs) includes both ocular and non-ocular (systemic) AEs. Multiple occurrences of the same AE in one individual are counted only once. Investigators sought information on AEs at each contact with the participants. All AEs were recorded and the investigator made an assessment of seriousness, severity, and causality of each AE. AEs of special interest included the following: Cases of potential drug-induced liver injury that include an elevated ALT or AST in combination with either an elevated bilirubin or clinical jaundice, as defined by Hy's Law; Suspected transmission of an infectious agent by the study drug; Sight-threatening AEs that cause a drop in visual acuity (VA) score ≥30 letters lasting more than 1 hour, require surgical or medical intervention to prevent permanent loss of sight, or are associated with severe intraocular inflammation (IOI).

    Time frame: From first dose of study drug through end of study (up to 112 weeks)

  39. Percentage of Participants With at Least One Ocular Adverse Event in the Study Eye or the Fellow Eye

    This analysis of adverse events (AEs) only includes ocular AEs, which are categorized as having occurred either in the study eye or the fellow eye. Multiple occurrences of the same AE in one individual are counted only once. Investigators sought information on AEs at each contact with the participants. All AEs were recorded and the investigator made an assessment of seriousness, severity, and causality of each AE. Ocular AEs of special interest included the following: Suspected transmission of an infectious agent by the study drug; Sight-threatening AEs that cause a drop in visual acuity (VA) score ≥30 letters lasting more than 1 hour, require surgical or medical intervention to prevent permanent loss of sight, or are associated with severe intraocular inflammation (IOI).

    Time frame: From first dose of study drug through end of study (up to 112 weeks)

  40. Percentage of Participants With at Least One Non-Ocular Adverse Event

    This analysis of adverse events (AEs) only includes non-ocular (systemic) AEs. Multiple occurrences of the same AE in one individual are counted only once. Investigators sought information on AEs at each contact with the participants. All AEs were recorded and the investigator made an assessment of seriousness, severity, and causality of each AE. The non-ocular AE of special interest was: Cases of potential drug-induced liver injury that include an elevated ALT or AST in combination with either an elevated bilirubin or clinical jaundice, as defined by Hy's Law.

    Time frame: From first dose of study drug through end of study (up to 112 weeks)

  41. Plasma Concentration of Faricimab Over Time

    Faricimab concentration in plasma was determined using a validated immunoassay method.

    Time frame: Pre-dose at Baseline, Weeks 4, 16, 20, 48, 76, and 112

  42. Percentage of Participants Who Tested Positive for Treatment-Emergent Anti-Drug Antibodies Against Faricimab During the Study

    Anti-drug antibodies (ADAs) against fariciamb were detected in plasma using a validated bridging enzyme-linked immunosorbent assay (ELISA). The percentage of participants with treatment-emergent ADA-positive samples includes post-baseline evaluable participants with at least one treatment-induced (defined as having an ADA-negative sample or missing sample at baseline and any positive post-baseline sample) or treatment-boosted (defined as having an ADA-positive sample at baseline and any positive post-baseline sample with a titer that is equal to or greater than 4-fold baseline titer) ADA-positive sample during the study treatment period.

    Time frame: Pre-dose at Baseline, Weeks 4, 20, 48, 76, and 112

07

Results

Posted May 4, 2022

Participant flow

Participant flow — Overall Study
MilestoneArm A: FaricimabArm B: Aflibercept
Started331327
Received at least one dose of study drug331326
Completed up to week 48321309
Completed297273
Not completed3454
Withdrew: Withdrawal by subject1622
Withdrew: Death1014
Withdrew: Adverse event35
Withdrew: Physician decision17
Withdrew: Lost to follow-up13
Withdrew: Protocol violation11
Withdrew: Lack of efficacy11
Withdrew: Not eligible01
Withdrew: Other10

Outcome measures

PrimaryChange From Baseline in BCVA in the Study Eye Averaged Over Weeks 40, 44, and 48

Best Corrected Visual Acuity (BCVA) was measured on the Early Treatment Diabetic Retinopathy Study (ETDRS) chart at a starting distance of 4 meters. The BCVA letter score ranges from 0 to 100 (best score), and a gain in BCVA from baseline indicates an improvement in visual acuity. The Mixed Model of Repeated Measures (MMRM) analysis adjusted for treatment arm, visit, visit-by-treatment arm interaction, baseline BCVA (continuous), baseline BCVA (≥74, 73-55, and ≤54 letters), baseline LLD (\<33 and ≥33 letters), and region (U.S. and Canada, Asia, and rest of the world). An unstructured covariance structure was used. Treatment policy strategy (i.e., all observed values used) and hypothetical strategy (i.e., all values censored after occurrence of the intercurrent event) were applied to non-COVID-19 related and COVID-19 related intercurrent events, respectively. Missing data were implicitly imputed by MMRM. Invalid BCVA values were excluded from analysis. 95% CI is a rounding of 95.03% CI.

Time frame:
From Baseline through Week 48
Reported as:
Mean · ETDRS Letters
Change From Baseline in BCVA in the Study Eye Averaged Over Weeks 40, 44, and 48
ETDRS LettersArm A: FaricimabArm B: Aflibercept
Change From Baseline in BCVA in the Study Eye Averaged Over Weeks 40, 44, and 486.6 (5.3 to 7.8)6.6 (5.3 to 7.8)
Statistical analysis
  • Arm A: Faricimab vs Arm B: Aflibercept · Adjusted mean difference: 0.0 · 95% CI -1.7 to 1.8The treatment difference in adjusted means of change from baseline BCVA is the calculated difference of Arm A: Faricimab and Arm B: Aflibercept. MMRM adjustments are listed in the outcome measure description.
SecondaryChange From Baseline in BCVA in the Study Eye Averaged Over Weeks 52, 56, and 60

Best Corrected Visual Acuity (BCVA) was measured on the Early Treatment Diabetic Retinopathy Study (ETDRS) chart at a starting distance of 4 meters. The BCVA letter score ranges from 0 to 100 (best score), and a gain in BCVA from baseline indicates an improvement in visual acuity. The Mixed Model of Repeated Measures (MMRM) analysis adjusted for treatment arm, visit, visit-by-treatment arm interaction, baseline BCVA (continuous), baseline BCVA (≥74, 73-55, and ≤54 letters), baseline LLD (\<33 and ≥33 letters), and region (U.S. and Canada, Asia, and rest of the world). An unstructured covariance structure was used. Treatment policy strategy (i.e., all observed values used) and hypothetical strategy (i.e., all values censored after occurrence of the intercurrent event) were applied to non-COVID-19 related and COVID-19 related intercurrent events, respectively. Missing data were implicitly imputed by MMRM. Invalid BCVA values were excluded from analysis. 95% CI is a rounding of 95.03% CI.

Time frame:
From Baseline through Week 60
Reported as:
Mean · ETDRS Letters
Change From Baseline in BCVA in the Study Eye Averaged Over Weeks 52, 56, and 60
ETDRS LettersArm A: FaricimabArm B: Aflibercept
Change From Baseline in BCVA in the Study Eye Averaged Over Weeks 52, 56, and 606.6 (5.3 to 7.9)7.1 (5.8 to 8.4)
Statistical analysis
  • Arm A: Faricimab vs Arm B: Aflibercept · Adjusted mean difference: -0.6 · 95% CI -2.4 to 1.3The treatment difference in adjusted means of change from baseline BCVA is the calculated difference of Arm A: Faricimab and Arm B: Aflibercept. MMRM adjustments are listed in the outcome measure description.
SecondaryChange From Baseline in BCVA in the Study Eye Over Time

Best Corrected Visual Acuity (BCVA) was measured on the Early Treatment Diabetic Retinopathy Study (ETDRS) chart at a starting distance of 4 meters. The BCVA letter score ranges from 0 to 100 (best score), and a gain in BCVA from baseline indicates an improvement in visual acuity. The Mixed Model of Repeated Measures (MMRM) analysis adjusted for treatment arm, visit, visit-by-treatment arm interaction, baseline BCVA (continuous), baseline BCVA (≥74, 73-55, and ≤54 letters), baseline LLD (\<33 and ≥33 letters), and region (U.S. and Canada, Asia, and rest of the world). An unstructured covariance structure was used. Treatment policy strategy (i.e., all observed values used) and hypothetical strategy (i.e., all values censored after occurrence of the intercurrent event) were applied to non-COVID-19 related and COVID-19 related intercurrent events, respectively. Missing data were implicitly imputed by MMRM. Invalid BCVA values were excluded from analysis. 95% CI is a rounding of 95.03% CI.

Time frame:
Baseline, Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52, 56, 60, 64, 68, 72, 76, 80, 84, 88, 92, 96, 100, 104, 108, and 112
Reported as:
Mean · ETDRS Letters
Change From Baseline in BCVA in the Study Eye Over Time
ETDRS LettersArm A: FaricimabArm B: Aflibercept
Week 45.1 (4.2 to 5.9)4.3 (3.5 to 5.2)
Week 86.0 (5.1 to 6.9)5.8 (4.9 to 6.8)
Week 127.0 (6.1 to 8.0)6.4 (5.4 to 7.4)
Week 166.7 (5.6 to 7.7)6.4 (5.4 to 7.4)
Week 207.0 (5.9 to 8.1)6.8 (5.7 to 7.9)
Week 247.0 (5.8 to 8.1)6.5 (5.4 to 7.6)
Week 287.1 (5.9 to 8.2)6.8 (5.6 to 7.9)
Week 327.2 (6.0 to 8.3)6.9 (5.7 to 8.0)
Week 366.7 (5.5 to 7.9)6.8 (5.6 to 8.0)
Week 406.8 (5.5 to 8.1)6.7 (5.4 to 8.0)
Week 446.5 (5.3 to 7.8)6.4 (5.2 to 7.7)
Week 486.5 (5.1 to 7.8)6.4 (5.0 to 7.7)
Week 526.4 (5.1 to 7.7)6.9 (5.5 to 8.3)
Week 567.1 (5.7 to 8.4)7.4 (6.0 to 8.7)
Week 606.3 (4.9 to 7.7)6.9 (5.5 to 8.3)
Week 646.5 (5.1 to 8.0)6.1 (4.7 to 7.6)
Week 686.2 (4.8 to 7.6)6.7 (5.3 to 8.1)
Week 726.4 (4.9 to 7.8)6.2 (4.8 to 7.7)
Week 766.4 (4.9 to 7.9)6.0 (4.6 to 7.5)
Week 805.9 (4.4 to 7.4)5.6 (4.1 to 7.2)
Week 845.9 (4.3 to 7.5)5.8 (4.2 to 7.3)
Week 885.6 (4.1 to 7.1)5.4 (3.9 to 7.0)
Week 925.7 (4.2 to 7.2)5.4 (3.9 to 7.0)
Week 965.4 (3.9 to 7.0)5.5 (3.9 to 7.0)
Week 1005.2 (3.6 to 6.8)4.9 (3.3 to 6.5)
Week 1045.0 (3.4 to 6.6)5.3 (3.7 to 6.9)
Week 1085.2 (3.5 to 6.8)5.4 (3.7 to 7.0)
Week 1124.8 (3.2 to 6.5)4.8 (3.1 to 6.5)
SecondaryPercentage of Participants Gaining Greater Than or Equal to (≥)15, ≥10, ≥5, or ≥0 Letters From the Baseline BCVA in the Study Eye Averaged Over Weeks 40, 44, and 48

BCVA was measured on the ETDRS chart at a starting distance of 4 meters. The BCVA letter score ranges from 0 to 100 (best score), and a gain in BCVA from baseline indicates an improvement in visual acuity. For each participant, an average BCVA value was calculated across the three visits, and this averaged value was used to determine if the endpoint was met. The results were summarized as the percentage of participants per treatment arm who met the endpoint. The weighted percentage of participants was based on the Cochran-Mantel Haenszel (CMH) weights stratified by baseline BCVA (≥74 letters, 73-55 letters, and ≤54 letters), baseline LLD (≥33 letters and \<33 letters), and region (U.S. and Canada vs. rest of the world). Treatment policy strategy and hypothetical strategy were applied to non-COVID-19 related and COVID-19 related intercurrent events, respectively. Missing data were not imputed. Invalid BCVA values were excluded. 95% confidence interval (CI) is a rounding of 95.03% CI.

Time frame:
Baseline, average of Weeks 40, 44, and 48
Reported as:
Number · Percentage of participants
Percentage of Participants Gaining Greater Than or Equal to (≥)15, ≥10, ≥5, or ≥0 Letters From the Baseline BCVA in the Study Eye Averaged Over Weeks 40, 44, and 48
Percentage of participantsArm A: FaricimabArm B: Aflibercept
Gaining ≥15 Letters20.2 (15.9 to 24.6)22.2 (17.7 to 26.8)
Gaining ≥10 Letters39.2 (34.1 to 44.4)35.8 (30.6 to 40.9)
Gaining ≥5 Letters60.5 (55.2 to 65.7)59.4 (53.9 to 64.9)
Gaining ≥0 Letters82.2 (77.9 to 86.4)79.1 (74.5 to 83.6)
Statistical analysis
  • Arm A: Faricimab vs Arm B: Aflibercept · Difference in cmh weighted percentage: -2.0 · 95% CI -8.3 to 4.3The treatment difference in CMH weighted percentage of participants gaining ≥15 letters is the calculated difference of Arm A: Faricimab and Arm B: Aflibercept.
  • Arm A: Faricimab vs Arm B: Aflibercept · Difference in cmh weighted percentage: 3.4 · 95% CI -3.9 to 10.7The treatment difference in CMH weighted percentage of participants gaining ≥10 letters is the calculated difference of Arm A: Faricimab and Arm B: Aflibercept.
  • Arm A: Faricimab vs Arm B: Aflibercept · Difference in cmh weighted percentage: 1.0 · 95% CI -6.6 to 8.6The treatment difference in CMH weighted percentage of participants gaining ≥5 letters is the calculated difference of Arm A: Faricimab and Arm B: Aflibercept.
  • Arm A: Faricimab vs Arm B: Aflibercept · Difference in cmh weighted percentage: 3.1 · 95% CI -3.1 to 9.3The treatment difference in CMH weighted percentage of participants gaining ≥0 letters is the calculated difference of Arm A: Faricimab and Arm B: Aflibercept.
SecondaryPercentage of Participants Gaining ≥15 Letters From the Baseline BCVA in the Study Eye Averaged Over Weeks 52, 56, and 60

BCVA was measured on the ETDRS chart at a starting distance of 4 meters. The BCVA letter score ranges from 0 to 100 (best score), and a gain in BCVA from baseline indicates an improvement in visual acuity. For each participant, an average BCVA value was calculated across the three visits, and this averaged value was used to determine if the endpoint was met. The results were summarized as the percentage of participants per treatment arm who met the endpoint. The weighted percentage of participants was based on the Cochran-Mantel Haenszel (CMH) weights stratified by baseline BCVA (≥74 letters, 73-55 letters, and ≤54 letters), baseline LLD (≥33 letters and \<33 letters), and region (U.S. and Canada vs. rest of the world). Treatment policy strategy and hypothetical strategy were applied to non-COVID-19 related and COVID-19 related intercurrent events, respectively. Missing data were not imputed. Invalid BCVA values were excluded. 95% confidence interval (CI) is a rounding of 95.03% CI.

Time frame:
Baseline, average of Weeks 52, 56, and 60
Reported as:
Number · Percentage of participants
Percentage of Participants Gaining ≥15 Letters From the Baseline BCVA in the Study Eye Averaged Over Weeks 52, 56, and 60
Percentage of participantsArm A: FaricimabArm B: Aflibercept
Percentage of Participants Gaining ≥15 Letters From the Baseline BCVA in the Study Eye Averaged Over Weeks 52, 56, and 6022.6 (18.1 to 27.1)23.7 (19.1 to 28.4)
Statistical analysis
  • Arm A: Faricimab vs Arm B: Aflibercept · Difference in cmh weighted percentage: -1.2 · 95% CI -7.7 to 5.3The treatment difference in CMH weighted percentage of participants gaining ≥15 letters is the calculated difference of Arm A: Faricimab and Arm B: Aflibercept.
SecondaryPercentage of Participants Gaining ≥15 Letters From the Baseline BCVA in the Study Eye Over Time

Best Corrected Visual Acuity (BCVA) was measured on the Early Treatment Diabetic Retinopathy Study (ETDRS) chart at a starting distance of 4 meters. The BCVA letter score ranges from 0 to 100 (best score), and a gain in BCVA letter score from baseline indicates an improvement in visual acuity. The weighted percentage of participants was based on the Cochran-Mantel Haenszel (CMH) weights stratified by baseline BCVA (≥74 letters, 73-55 letters, and ≤54 letters), baseline LLD (≥33 letters and \<33 letters), and region (U.S. and Canada vs. rest of the world; Asia and rest of the world were combined). Treatment policy strategy (i.e., all observed values used) and hypothetical strategy (i.e., all values censored after the occurrence of the intercurrent event) were applied to non-COVID-19 related and COVID-19 related intercurrent events, respectively. Missing data were not imputed. Invalid BCVA values were excluded from analysis. 95% confidence interval (CI) is a rounding of 95.03% CI.

Time frame:
Baseline, Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52, 56, 60, 64, 68, 72, 76, 80, 84, 88, 92, 96, 100, 104, 108, and 112
Reported as:
Number · Percentage of participants
Percentage of Participants Gaining ≥15 Letters From the Baseline BCVA in the Study Eye Over Time
Percentage of participantsArm A: FaricimabArm B: Aflibercept
Week 410.5 (7.2 to 13.7)9.5 (6.4 to 12.6)
Week 813.9 (10.3 to 17.5)13.5 (10.0 to 17.1)
Week 1217.7 (13.7 to 21.6)17.2 (13.3 to 21.1)
Week 1617.3 (13.3 to 21.3)17.7 (13.6 to 21.8)
Week 2020.2 (15.9 to 24.4)20.2 (15.9 to 24.4)
Week 2419.3 (14.9 to 23.6)18.9 (14.6 to 23.3)
Week 2823.7 (19.1 to 28.3)20.8 (16.1 to 25.4)
Week 3222.6 (18.0 to 27.2)19.5 (15.1 to 23.9)
Week 3622.2 (17.7 to 26.6)20.6 (16.1 to 25.0)
Week 4023.7 (19.0 to 28.3)25.4 (20.6 to 30.1)
Week 4421.5 (17.1 to 26.0)22.4 (17.7 to 27.1)
Week 4822.3 (17.7 to 26.9)23.1 (18.3 to 27.8)
Week 5222.7 (18.1 to 27.2)23.4 (18.7 to 28.1)
Week 5625.9 (21.1 to 30.7)27.0 (22.0 to 32.0)
Week 6022.6 (18.1 to 27.1)25.8 (20.9 to 30.7)
Week 6425.4 (20.6 to 30.2)21.2 (16.5 to 25.9)
Week 6824.5 (19.7 to 29.3)24.9 (20.0 to 29.8)
Week 7222.6 (17.9 to 27.2)27.1 (22.0 to 32.1)
Week 7622.1 (17.4 to 26.8)24.9 (20.1 to 29.8)
Week 8022.9 (18.1 to 27.7)25.8 (20.8 to 30.7)
Week 8423.7 (18.9 to 28.5)25.6 (20.6 to 30.6)
Week 8824.1 (19.3 to 29.0)24.4 (19.5 to 29.3)
Week 9222.5 (17.8 to 27.2)24.8 (19.9 to 29.8)
Week 9625.7 (20.8 to 30.6)25.5 (20.5 to 30.6)
Week 10024.8 (19.9 to 29.8)23.1 (18.3 to 28.0)
Week 10422.5 (17.7 to 27.3)24.6 (19.6 to 29.5)
Week 10821.6 (16.8 to 26.3)22.3 (17.5 to 27.1)
Week 11225.2 (20.3 to 30.1)22.5 (17.8 to 27.1)
SecondaryPercentage of Participants Gaining ≥10 Letters From the Baseline BCVA in the Study Eye Over Time

Best Corrected Visual Acuity (BCVA) was measured on the Early Treatment Diabetic Retinopathy Study (ETDRS) chart at a starting distance of 4 meters. The BCVA letter score ranges from 0 to 100 (best score), and a gain in BCVA letter score from baseline indicates an improvement in visual acuity. The weighted percentage of participants was based on the Cochran-Mantel Haenszel (CMH) weights stratified by baseline BCVA (≥74 letters, 73-55 letters, and ≤54 letters), baseline LLD (≥33 letters and \<33 letters), and region (U.S. and Canada vs. rest of the world; Asia and rest of the world were combined). Treatment policy strategy (i.e., all observed values used) and hypothetical strategy (i.e., all values censored after the occurrence of the intercurrent event) were applied to non-COVID-19 related and COVID-19 related intercurrent events, respectively. Missing data were not imputed. Invalid BCVA values were excluded from analysis. 95% confidence interval (CI) is a rounding of 95.03% CI.

Time frame:
Baseline, Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52, 56, 60, 64, 68, 72, 76, 80, 84, 88, 92, 96, 100, 104, 108, and 112
Reported as:
Number · Percentage of participants
Percentage of Participants Gaining ≥10 Letters From the Baseline BCVA in the Study Eye Over Time
Percentage of participantsArm A: FaricimabArm B: Aflibercept
Week 424.2 (19.8 to 28.7)22.1 (17.7 to 26.5)
Week 832.4 (27.5 to 37.2)28.7 (24.1 to 33.4)
Week 1234.2 (29.3 to 39.1)34.6 (29.5 to 39.7)
Week 1635.3 (30.3 to 40.4)34.2 (29.2 to 39.3)
Week 2037.8 (32.7 to 42.9)34.3 (29.2 to 39.4)
Week 2439.2 (33.8 to 44.5)35.2 (29.9 to 40.5)
Week 2840.5 (35.1 to 45.8)36.0 (30.5 to 41.4)
Week 3240.5 (35.1 to 46.0)35.0 (29.7 to 40.3)
Week 3638.9 (33.6 to 44.2)38.9 (33.5 to 44.3)
Week 4040.9 (35.5 to 46.3)39.3 (34.0 to 44.7)
Week 4442.3 (36.8 to 47.8)39.5 (34.1 to 45.0)
Week 4841.0 (35.5 to 46.5)38.6 (33.2 to 43.9)
Week 5244.2 (38.8 to 49.7)42.1 (36.6 to 47.6)
Week 5644.2 (38.8 to 49.7)43.6 (38.1 to 49.2)
Week 6043.1 (37.6 to 48.6)42.4 (36.8 to 47.9)
Week 6444.0 (38.5 to 49.5)41.1 (35.4 to 46.8)
Week 6840.1 (34.7 to 45.5)40.7 (35.3 to 46.2)
Week 7242.0 (36.5 to 47.4)38.9 (33.4 to 44.3)
Week 7642.2 (36.7 to 47.8)40.7 (35.1 to 46.2)
Week 8044.2 (38.6 to 49.9)41.9 (36.2 to 47.6)
Week 8442.7 (37.2 to 48.3)41.4 (35.6 to 47.2)
Week 8840.3 (34.8 to 45.9)39.4 (33.7 to 45.1)
Week 9242.1 (36.5 to 47.8)41.0 (35.3 to 46.7)
Week 9641.1 (35.5 to 46.7)39.1 (33.3 to 45.0)
Week 10040.2 (34.6 to 45.7)34.6 (29.0 to 40.1)
Week 10444.0 (38.3 to 49.7)36.2 (30.5 to 41.9)
Week 10841.7 (36.0 to 47.4)38.0 (32.2 to 43.8)
Week 11241.3 (35.7 to 47.0)35.0 (29.6 to 40.5)
SecondaryPercentage of Participants Gaining ≥5 Letters From the Baseline BCVA in the Study Eye Over Time

Best Corrected Visual Acuity (BCVA) was measured on the Early Treatment Diabetic Retinopathy Study (ETDRS) chart at a starting distance of 4 meters. The BCVA letter score ranges from 0 to 100 (best score), and a gain in BCVA letter score from baseline indicates an improvement in visual acuity. The weighted percentage of participants was based on the Cochran-Mantel Haenszel (CMH) weights stratified by baseline BCVA (≥74 letters, 73-55 letters, and ≤54 letters), baseline LLD (≥33 letters and \<33 letters), and region (U.S. and Canada vs. rest of the world; Asia and rest of the world were combined). Treatment policy strategy (i.e., all observed values used) and hypothetical strategy (i.e., all values censored after the occurrence of the intercurrent event) were applied to non-COVID-19 related and COVID-19 related intercurrent events, respectively. Missing data were not imputed. Invalid BCVA values were excluded from analysis. 95% confidence interval (CI) is a rounding of 95.03% CI.

Time frame:
Baseline, Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52, 56, 60, 64, 68, 72, 76, 80, 84, 88, 92, 96, 100, 104, 108, and 112
Reported as:
Number · Percentage of participants
Percentage of Participants Gaining ≥5 Letters From the Baseline BCVA in the Study Eye Over Time
Percentage of participantsArm A: FaricimabArm B: Aflibercept
Week 447.8 (42.6 to 53.0)47.5 (42.2 to 52.8)
Week 856.8 (51.6 to 62.0)54.6 (49.3 to 59.8)
Week 1263.9 (58.9 to 68.9)57.6 (52.3 to 62.9)
Week 1661.7 (56.5 to 66.8)59.6 (54.3 to 64.9)
Week 2064.1 (59.0 to 69.2)60.9 (55.6 to 66.3)
Week 2462.2 (56.8 to 67.6)60.2 (54.7 to 65.7)
Week 2863.6 (58.2 to 68.9)60.5 (54.8 to 66.2)
Week 3263.3 (58.0 to 68.7)60.1 (54.6 to 65.6)
Week 3661.4 (56.0 to 66.9)60.4 (54.9 to 65.9)
Week 4063.5 (58.1 to 68.9)60.9 (55.5 to 66.4)
Week 4460.1 (54.6 to 65.6)62.3 (56.7 to 67.8)
Week 4860.0 (54.5 to 65.6)63.5 (57.9 to 69.1)
Week 5263.5 (58.1 to 69.0)67.2 (61.7 to 72.6)
Week 5664.1 (58.7 to 69.5)66.5 (61.0 to 72.0)
Week 6061.6 (56.1 to 67.2)65.5 (59.9 to 71.0)
Week 6465.2 (59.8 to 70.6)63.1 (57.5 to 68.8)
Week 6863.0 (57.4 to 68.5)64.0 (58.5 to 69.6)
Week 7264.1 (58.6 to 69.6)66.6 (60.9 to 72.2)
Week 7663.9 (58.2 to 69.6)58.7 (53.0 to 64.4)
Week 8063.3 (57.7 to 68.9)62.3 (56.6 to 67.9)
Week 8461.6 (56.1 to 67.2)64.3 (58.6 to 70.1)
Week 8862.6 (57.1 to 68.1)60.7 (54.9 to 66.5)
Week 9262.7 (57.1 to 68.3)58.3 (52.6 to 64.0)
Week 9661.3 (55.6 to 67.0)61.0 (55.1 to 67.0)
Week 10061.7 (56.1 to 67.3)56.9 (50.9 to 62.9)
Week 10460.3 (54.6 to 66.0)59.3 (53.3 to 65.3)
Week 10862.4 (56.8 to 68.0)58.0 (51.8 to 64.1)
Week 11259.9 (54.2 to 65.6)59.4 (53.4 to 65.3)
SecondaryPercentage of Participants Gaining ≥0 Letters From the Baseline BCVA in the Study Eye Over Time

Best Corrected Visual Acuity (BCVA) was measured on the Early Treatment Diabetic Retinopathy Study (ETDRS) chart at a starting distance of 4 meters. The BCVA letter score ranges from 0 to 100 (best score), and a gain in BCVA letter score from baseline indicates an improvement in visual acuity. The weighted percentage of participants was based on the Cochran-Mantel Haenszel (CMH) weights stratified by baseline BCVA (≥74 letters, 73-55 letters, and ≤54 letters), baseline LLD (≥33 letters and \<33 letters), and region (U.S. and Canada vs. rest of the world; Asia and rest of the world were combined). Treatment policy strategy (i.e., all observed values used) and hypothetical strategy (i.e., all values censored after the occurrence of the intercurrent event) were applied to non-COVID-19 related and COVID-19 related intercurrent events, respectively. Missing data were not imputed. Invalid BCVA values were excluded from analysis. 95% confidence interval (CI) is a rounding of 95.03% CI.

Time frame:
Baseline, Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52, 56, 60, 64, 68, 72, 76, 80, 84, 88, 92, 96, 100, 104, 108, and 112
Reported as:
Number · Percentage of participants
Percentage of Participants Gaining ≥0 Letters From the Baseline BCVA in the Study Eye Over Time
Percentage of participantsArm A: FaricimabArm B: Aflibercept
Week 480.5 (76.3 to 84.7)74.2 (69.5 to 78.9)
Week 882.3 (78.3 to 86.3)80.3 (76.0 to 84.5)
Week 1284.1 (80.3 to 88.0)81.0 (76.8 to 85.1)
Week 1682.6 (78.5 to 86.6)83.0 (78.9 to 87.0)
Week 2084.8 (80.9 to 88.6)83.1 (79.1 to 87.2)
Week 2482.8 (78.6 to 86.9)82.0 (77.6 to 86.4)
Week 2882.7 (78.5 to 86.8)83.0 (78.7 to 87.4)
Week 3280.3 (75.9 to 84.7)82.2 (77.8 to 86.5)
Week 3681.2 (76.8 to 85.6)76.5 (71.7 to 81.3)
Week 4082.0 (77.6 to 86.3)77.6 (72.9 to 82.3)
Week 4484.0 (79.8 to 88.2)78.6 (73.9 to 83.2)
Week 4882.7 (78.3 to 87.1)78.9 (74.1 to 83.6)
Week 5279.4 (74.8 to 84.0)84.7 (80.5 to 88.9)
Week 5680.7 (76.1 to 85.2)82.6 (78.2 to 87.0)
Week 6078.9 (74.2 to 83.6)81.5 (77.0 to 86.0)
Week 6481.3 (76.8 to 85.8)81.1 (76.5 to 85.7)
Week 6880.5 (76.0 to 85.1)80.4 (75.8 to 85.0)
Week 7279.5 (74.8 to 84.1)78.8 (74.0 to 83.6)
Week 7681.0 (76.4 to 85.6)79.8 (75.2 to 84.5)
Week 8080.0 (75.3 to 84.7)76.0 (71.0 to 81.1)
Week 8478.7 (73.9 to 83.5)81.0 (76.3 to 85.7)
Week 8878.7 (73.9 to 83.5)80.6 (75.9 to 85.4)
Week 9281.3 (76.7 to 85.8)76.3 (71.2 to 81.4)
Week 9676.3 (71.3 to 81.3)77.5 (72.5 to 82.6)
Week 10075.7 (70.8 to 80.7)74.8 (69.6 to 80.0)
Week 10476.6 (71.6 to 81.6)79.0 (74.0 to 84.0)
Week 10878.8 (74.0 to 83.6)76.9 (71.7 to 82.1)
Week 11274.6 (69.5 to 79.8)77.4 (72.3 to 82.5)
SecondaryPercentage of Participants Avoiding a Loss of ≥15, ≥10, or ≥5 Letters From the Baseline BCVA in the Study Eye Averaged Over Weeks 40, 44, and 48

Best Corrected Visual Acuity (BCVA) was measured on the Early Treatment Diabetic Retinopathy Study (ETDRS) chart at a starting distance of 4 meters. For each participant, an average BCVA value was calculated across the three visits, and this averaged value was then used to determine if the endpoint was met. The results were summarized as the percentage of participants per treatment arm who met the endpoint. The weighted percentage of participants was based on the Cochran-Mantel Haenszel (CMH) weights stratified by baseline BCVA (≥74 letters, 73-55 letters, and ≤54 letters), baseline LLD (≥33 letters and \<33 letters), and region (U.S. and Canada vs. rest of the world). Treatment policy strategy and hypothetical strategy were applied to non-COVID-19 related and COVID-19 related intercurrent events, respectively. Missing data were not imputed. Invalid BCVA values were excluded. 95% confidence interval (CI) is a rounding of 95.03% CI.

Time frame:
Baseline, average of Weeks 40, 44, and 48
Reported as:
Number · Percentage of participants
Percentage of Participants Avoiding a Loss of ≥15, ≥10, or ≥5 Letters From the Baseline BCVA in the Study Eye Averaged Over Weeks 40, 44, and 48
Percentage of participantsArm A: FaricimabArm B: Aflibercept
Avoiding a Loss of ≥15 Letters95.8 (93.6 to 98.0)97.3 (95.5 to 99.1)
Avoiding a Loss of ≥10 Letters93.8 (91.1 to 96.4)94.6 (92.2 to 97.1)
Avoiding a Loss of ≥5 Letters91.2 (88.0 to 94.3)88.5 (85.0 to 92.0)
Statistical analysis
  • Arm A: Faricimab vs Arm B: Aflibercept · Difference in cmh weighted percentage: -1.5 · 95% CI -4.4 to 1.3The treatment difference in CMH weighted percentage of participants avoiding a loss of ≥15 letters is the calculated difference of Arm A: Faricimab and Arm B: Aflibercept.
  • Arm A: Faricimab vs Arm B: Aflibercept · Difference in cmh weighted percentage: -0.9 · 95% CI -4.5 to 2.8The treatment difference in CMH weighted percentage of participants avoiding a loss of ≥10 letters is the calculated difference of Arm A: Faricimab and Arm B: Aflibercept.
  • Arm A: Faricimab vs Arm B: Aflibercept · Difference in cmh weighted percentage: 2.6 · 95% CI -2.1 to 7.3The treatment difference in CMH weighted percentage of participants avoiding a loss of ≥5 letters is the calculated difference of Arm A: Faricimab and Arm B: Aflibercept.
SecondaryPercentage of Participants Avoiding a Loss of ≥15 Letters From the Baseline BCVA in the Study Eye Averaged Over Weeks 52, 56, and 60

Best Corrected Visual Acuity (BCVA) was measured on the Early Treatment Diabetic Retinopathy Study (ETDRS) chart at a starting distance of 4 meters. For each participant, an average BCVA value was calculated across the three visits, and this averaged value was then used to determine if the endpoint was met. The results were summarized as the percentage of participants per treatment arm who met the endpoint. The weighted percentage of participants was based on the Cochran-Mantel Haenszel (CMH) weights stratified by baseline BCVA (≥74 letters, 73-55 letters, and ≤54 letters), baseline LLD (≥33 letters and \<33 letters), and region (U.S. and Canada vs. rest of the world). Treatment policy strategy and hypothetical strategy were applied to non-COVID-19 related and COVID-19 related intercurrent events, respectively. Missing data were not imputed. Invalid BCVA values were excluded. 95% confidence interval (CI) is a rounding of 95.03% CI.

Time frame:
Baseline, average of Weeks 52, 56, and 60
Reported as:
Number · Percentage of participants
Percentage of Participants Avoiding a Loss of ≥15 Letters From the Baseline BCVA in the Study Eye Averaged Over Weeks 52, 56, and 60
Percentage of participantsArm A: FaricimabArm B: Aflibercept
Percentage of Participants Avoiding a Loss of ≥15 Letters From the Baseline BCVA in the Study Eye Averaged Over Weeks 52, 56, and 6096.5 (94.4 to 98.6)96.1 (94.0 to 98.3)
Statistical analysis
  • Arm A: Faricimab vs Arm B: Aflibercept · Difference in cmh weighted percentage: 0.4 · 95% CI -2.6 to 3.3The treatment difference in CMH weighted percentage of participants avoiding a loss of ≥15 letters is the calculated difference of Arm A: Faricimab and Arm B: Aflibercept.
SecondaryPercentage of Participants Avoiding a Loss of ≥15 Letters From the Baseline BCVA in the Study Eye Over Time

Best Corrected Visual Acuity (BCVA) was measured on the Early Treatment Diabetic Retinopathy Study (ETDRS) chart at a starting distance of 4 meters. The weighted percentage of participants avoiding a loss of letters in BCVA from baseline was based on the Cochran-Mantel Haenszel (CMH) weights stratified by baseline BCVA (≥74 letters, 73-55 letters, and ≤54 letters), baseline LLD (≥33 letters and \<33 letters), and region (U.S. and Canada vs. rest of the world; Asia and rest of the world were combined). Treatment policy strategy (i.e., all observed values used) and hypothetical strategy (i.e., all values censored after the occurrence of the intercurrent event) were applied to non-COVID-19 related and COVID-19 related intercurrent events, respectively. Missing data were not imputed. Invalid BCVA values were excluded from analysis. 95% confidence interval (CI) is a rounding of 95.03% CI.

Time frame:
Baseline, Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52, 56, 60, 64, 68, 72, 76, 80, 84, 88, 92, 96, 100, 104, 108, and 112
Reported as:
Number · Percentage of participants
Percentage of Participants Avoiding a Loss of ≥15 Letters From the Baseline BCVA in the Study Eye Over Time
Percentage of participantsArm A: FaricimabArm B: Aflibercept
Week 499.4 (98.6 to 100.0)98.1 (96.7 to 99.6)
Week 898.5 (97.3 to 99.8)97.8 (96.3 to 99.4)
Week 1298.5 (97.3 to 99.8)98.1 (96.7 to 99.6)
Week 1697.6 (96.0 to 99.2)98.4 (97.0 to 99.8)
Week 2097.3 (95.5 to 99.0)98.4 (97.0 to 99.7)
Week 2496.6 (94.6 to 98.6)97.2 (95.4 to 99.1)
Week 2897.0 (95.1 to 98.9)97.8 (96.2 to 99.5)
Week 3297.0 (95.1 to 98.9)96.9 (95.0 to 98.9)
Week 3697.0 (95.2 to 98.9)96.5 (94.5 to 98.6)
Week 4096.2 (94.1 to 98.4)97.6 (95.9 to 99.3)
Week 4495.9 (93.6 to 98.1)96.4 (94.3 to 98.5)
Week 4895.8 (93.5 to 98.0)96.9 (95.0 to 98.8)
Week 5294.9 (92.5 to 97.4)96.8 (94.8 to 98.8)
Week 5696.1 (93.9 to 98.3)96.8 (94.8 to 98.8)
Week 6095.0 (92.5 to 97.5)96.1 (94.0 to 98.3)
Week 6496.4 (94.3 to 98.5)94.9 (92.3 to 97.4)
Week 6894.7 (92.1 to 97.2)96.0 (93.7 to 98.3)
Week 7294.5 (91.9 to 97.2)95.4 (92.9 to 97.9)
Week 7694.9 (92.3 to 97.4)93.7 (90.9 to 96.6)
Week 8093.9 (91.1 to 96.6)93.3 (90.4 to 96.3)
Week 8492.5 (89.5 to 95.5)93.8 (90.9 to 96.7)
Week 8894.1 (91.4 to 96.7)94.3 (91.5 to 97.0)
Week 9293.0 (90.2 to 95.9)94.6 (92.0 to 97.2)
Week 9692.6 (89.6 to 95.6)95.0 (92.5 to 97.6)
Week 10092.5 (89.5 to 95.5)93.9 (91.1 to 96.7)
Week 10492.9 (90.0 to 95.9)94.0 (91.0 to 96.9)
Week 10892.3 (89.2 to 95.3)93.3 (90.3 to 96.3)
Week 11291.8 (88.7 to 95.0)93.0 (89.9 to 96.1)
SecondaryPercentage of Participants Avoiding a Loss of ≥10 Letters From the Baseline BCVA in the Study Eye Over Time

Best Corrected Visual Acuity (BCVA) was measured on the Early Treatment Diabetic Retinopathy Study (ETDRS) chart at a starting distance of 4 meters. The weighted percentage of participants avoiding a loss of letters in BCVA from baseline was based on the Cochran-Mantel Haenszel (CMH) weights stratified by baseline BCVA (≥74 letters, 73-55 letters, and ≤54 letters), baseline LLD (≥33 letters and \<33 letters), and region (U.S. and Canada vs. rest of the world; Asia and rest of the world were combined). Treatment policy strategy (i.e., all observed values used) and hypothetical strategy (i.e., all values censored after the occurrence of the intercurrent event) were applied to non-COVID-19 related and COVID-19 related intercurrent events, respectively. Missing data were not imputed. Invalid BCVA values were excluded from analysis. 95% confidence interval (CI) is a rounding of 95.03% CI.

Time frame:
Baseline, Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52, 56, 60, 64, 68, 72, 76, 80, 84, 88, 92, 96, 100, 104, 108, and 112
Reported as:
Number · Percentage of participants
Percentage of Participants Avoiding a Loss of ≥10 Letters From the Baseline BCVA in the Study Eye Over Time
Percentage of participantsArm A: FaricimabArm B: Aflibercept
Week 498.5 (97.2 to 99.8)96.2 (94.1 to 98.3)
Week 897.0 (95.3 to 98.7)96.9 (95.0 to 98.7)
Week 1297.0 (95.2 to 98.8)96.8 (94.9 to 98.7)
Week 1696.6 (94.7 to 98.5)96.8 (94.9 to 98.7)
Week 2095.2 (92.9 to 97.4)96.1 (94.0 to 98.2)
Week 2495.2 (92.9 to 97.6)95.5 (93.2 to 97.8)
Week 2895.0 (92.6 to 97.4)95.2 (92.7 to 97.7)
Week 3294.6 (92.1 to 97.1)95.9 (93.7 to 98.1)
Week 3695.3 (93.0 to 97.7)94.4 (91.8 to 97.0)
Week 4093.8 (91.1 to 96.5)94.6 (92.2 to 97.1)
Week 4494.1 (91.4 to 96.8)92.1 (89.1 to 95.1)
Week 4892.2 (89.2 to 95.3)94.8 (92.3 to 97.3)
Week 5291.4 (88.2 to 94.6)93.8 (91.1 to 96.6)
Week 5693.3 (90.5 to 96.2)95.0 (92.5 to 97.5)
Week 6091.4 (88.2 to 94.6)93.2 (90.4 to 96.1)
Week 6493.5 (90.7 to 96.4)92.3 (89.3 to 95.4)
Week 6891.9 (88.8 to 95.0)92.9 (89.9 to 96.0)
Week 7292.4 (89.3 to 95.5)91.6 (88.3 to 94.9)
Week 7693.1 (90.2 to 96.0)90.1 (86.5 to 93.6)
Week 8092.1 (89.0 to 95.2)89.9 (86.3 to 93.5)
Week 8490.3 (86.9 to 93.7)91.8 (88.4 to 95.1)
Week 8890.8 (87.5 to 94.1)92.3 (89.1 to 95.4)
Week 9290.7 (87.4 to 94.1)91.0 (87.6 to 94.5)
Week 9690.4 (87.0 to 93.8)92.6 (89.4 to 95.8)
Week 10090.7 (87.4 to 94.0)91.6 (88.3 to 94.9)
Week 10489.0 (85.4 to 92.7)92.2 (88.9 to 95.4)
Week 10888.5 (84.8 to 92.3)91.2 (87.7 to 94.7)
Week 11288.5 (84.7 to 92.2)89.5 (85.8 to 93.2)
SecondaryPercentage of Participants Avoiding a Loss of ≥5 Letters From the Baseline BCVA in the Study Eye Over Time

Best Corrected Visual Acuity (BCVA) was measured on the Early Treatment Diabetic Retinopathy Study (ETDRS) chart at a starting distance of 4 meters. The weighted percentage of participants avoiding a loss of letters in BCVA from baseline was based on the Cochran-Mantel Haenszel (CMH) weights stratified by baseline BCVA (≥74 letters, 73-55 letters, and ≤54 letters), baseline LLD (≥33 letters and \<33 letters), and region (U.S. and Canada vs. rest of the world; Asia and rest of the world were combined). Treatment policy strategy (i.e., all observed values used) and hypothetical strategy (i.e., all values censored after the occurrence of the intercurrent event) were applied to non-COVID-19 related and COVID-19 related intercurrent events, respectively. Missing data were not imputed. Invalid BCVA values were excluded from analysis. 95% confidence interval (CI) is a rounding of 95.03% CI.

Time frame:
Baseline, Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52, 56, 60, 64, 68, 72, 76, 80, 84, 88, 92, 96, 100, 104, 108, and 112
Reported as:
Number · Percentage of participants
Percentage of Participants Avoiding a Loss of ≥5 Letters From the Baseline BCVA in the Study Eye Over Time
Percentage of participantsArm A: FaricimabArm B: Aflibercept
Week 493.0 (90.4 to 95.6)91.8 (88.9 to 94.7)
Week 893.1 (90.4 to 95.7)94.1 (91.5 to 96.6)
Week 1293.3 (90.7 to 95.9)91.8 (88.8 to 94.7)
Week 1691.7 (88.7 to 94.6)90.8 (87.7 to 94.0)
Week 2092.0 (89.1 to 94.9)92.9 (90.0 to 95.7)
Week 2490.6 (87.4 to 93.9)91.7 (88.6 to 94.8)
Week 2891.0 (87.9 to 94.1)90.2 (86.7 to 93.7)
Week 3289.9 (86.5 to 93.2)91.0 (87.7 to 94.3)
Week 3690.7 (87.5 to 94.0)87.4 (83.6 to 91.2)
Week 4091.7 (88.6 to 94.9)88.1 (84.5 to 91.7)
Week 4490.9 (87.7 to 94.2)88.8 (85.3 to 92.3)
Week 4889.4 (85.9 to 93.0)88.6 (85.0 to 92.2)
Week 5288.9 (85.3 to 92.5)91.7 (88.6 to 94.8)
Week 5689.5 (86.0 to 93.0)88.8 (85.2 to 92.5)
Week 6086.7 (82.9 to 90.6)88.8 (85.2 to 92.4)
Week 6487.8 (84.1 to 91.6)86.0 (82.0 to 90.1)
Week 6888.2 (84.5 to 91.9)87.1 (83.2 to 91.0)
Week 7287.0 (83.1 to 90.9)87.3 (83.4 to 91.2)
Week 7687.1 (83.2 to 91.1)85.4 (81.2 to 89.5)
Week 8087.3 (83.5 to 91.2)82.8 (78.3 to 87.3)
Week 8484.1 (79.9 to 88.4)87.1 (83.1 to 91.2)
Week 8887.5 (83.7 to 91.3)86.6 (82.5 to 90.6)
Week 9287.0 (83.1 to 90.9)87.2 (83.2 to 91.2)
Week 9682.7 (78.4 to 87.1)86.2 (82.1 to 90.4)
Week 10085.9 (81.9 to 89.8)84.2 (79.9 to 88.5)
Week 10483.5 (79.1 to 87.8)85.4 (81.1 to 89.7)
Week 10884.1 (79.9 to 88.4)83.9 (79.4 to 88.5)
Week 11282.2 (77.7 to 86.7)84.4 (80.0 to 88.8)
SecondaryPercentage of Participants Gaining ≥15 Letters From the Baseline BCVA or Achieving BCVA Snellen Equivalent of 20/20 or Better (BCVA ≥84 Letters) in the Study Eye Averaged Over Weeks 40, 44, and 48

BCVA was measured on the ETDRS chart at a starting distance of 4 meters. The BCVA letter score ranges from 0 to 100 (best score), and a gain in BCVA from baseline indicates an improvement in visual acuity. For each participant, an average BCVA value was calculated across the three visits, and this averaged value was used to determine if the endpoint was met. The results were summarized as the percentage of participants per treatment arm who met the endpoint. The weighted percentage of participants was based on the Cochran-Mantel Haenszel (CMH) weights stratified by baseline BCVA (≥74 letters, 73-55 letters, and ≤54 letters), baseline LLD (≥33 letters and \<33 letters), and region (U.S. and Canada vs. rest of the world). Treatment policy strategy and hypothetical strategy were applied to non-COVID-19 related and COVID-19 related intercurrent events, respectively. Missing data were not imputed. Invalid BCVA values were excluded. 95% confidence interval (CI) is a rounding of 95.03% CI.

Time frame:
Baseline, average of Weeks 40, 44, and 48
Reported as:
Number · Percentage of participants
Percentage of Participants Gaining ≥15 Letters From the Baseline BCVA or Achieving BCVA Snellen Equivalent of 20/20 or Better (BCVA ≥84 Letters) in the Study Eye Averaged Over Weeks 40, 44, and 48
Percentage of participantsArm A: FaricimabArm B: Aflibercept
Percentage of Participants Gaining ≥15 Letters From the Baseline BCVA or Achieving BCVA Snellen Equivalent of 20/20 or Better (BCVA ≥84 Letters) in the Study Eye Averaged Over Weeks 40, 44, and 4824.5 (19.8 to 29.2)26.2 (21.2 to 31.1)
Statistical analysis
  • Arm A: Faricimab vs Arm B: Aflibercept · Difference in cmh weighted percentage: -1.7 · 95% CI -8.5 to 5.1The treatment difference in CMH weighted percentage of participants gaining ≥15 letters or achieving BCVA ≥84 letters is the calculated difference of Arm A: Faricimab and Arm B: Aflibercept.
SecondaryPercentage of Participants Gaining ≥15 Letters From the Baseline BCVA or Achieving BCVA Snellen Equivalent of 20/20 or Better (BCVA ≥84 Letters) in the Study Eye Over Time

Best Corrected Visual Acuity (BCVA) was measured on the Early Treatment Diabetic Retinopathy Study (ETDRS) chart at a starting distance of 4 meters. The BCVA letter score ranges from 0 to 100 (best score), and a gain in BCVA letter score from baseline indicates an improvement in visual acuity. The weighted percentage of participants was based on the Cochran-Mantel Haenszel (CMH) weights stratified by baseline BCVA (≥74 letters, 73-55 letters, and ≤54 letters), baseline LLD (≥33 letters and \<33 letters), and region (U.S. and Canada vs. rest of the world; Asia and rest of the world were combined). Treatment policy strategy (i.e., all observed values used) and hypothetical strategy (i.e., all values censored after the occurrence of the intercurrent event) were applied to non-COVID-19 related and COVID-19 related intercurrent events, respectively. Missing data were not imputed. Invalid BCVA values were excluded from analysis. 95% confidence interval (CI) is a rounding of 95.03% CI.

Time frame:
Baseline, Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52, 56, 60, 64, 68, 72, 76, 80, 84, 88, 92, 96, 100, 104, 108, and 112
Reported as:
Number · Percentage of participants
Percentage of Participants Gaining ≥15 Letters From the Baseline BCVA or Achieving BCVA Snellen Equivalent of 20/20 or Better (BCVA ≥84 Letters) in the Study Eye Over Time
Percentage of participantsArm A: FaricimabArm B: Aflibercept
Week 411.3 (7.9 to 14.6)12.4 (8.9 to 15.9)
Week 816.5 (12.5 to 20.4)16.1 (12.2 to 20.0)
Week 1222.0 (17.7 to 26.4)21.1 (16.7 to 25.4)
Week 1621.7 (17.4 to 26.1)20.7 (16.2 to 25.1)
Week 2024.9 (20.2 to 29.5)24.9 (20.2 to 29.6)
Week 2423.6 (18.9 to 28.3)23.7 (18.9 to 28.6)
Week 2827.7 (22.7 to 32.7)26.9 (21.8 to 32.1)
Week 3228.7 (23.6 to 33.8)23.2 (18.4 to 27.9)
Week 3625.9 (21.1 to 30.7)24.6 (19.7 to 29.5)
Week 4027.9 (22.9 to 32.9)31.1 (25.9 to 36.4)
Week 4427.2 (22.2 to 32.1)28.1 (22.8 to 33.3)
Week 4827.3 (22.3 to 32.4)28.3 (23.1 to 33.6)
Week 5229.2 (24.1 to 34.3)28.3 (23.1 to 33.5)
Week 5632.0 (26.7 to 37.2)31.5 (26.1 to 36.9)
Week 6027.5 (22.5 to 32.5)31.4 (26.0 to 36.8)
Week 6430.1 (25.0 to 35.3)27.1 (21.9 to 32.3)
Week 6828.3 (23.1 to 33.4)30.0 (24.6 to 35.3)
Week 7226.4 (21.4 to 31.4)31.5 (26.0 to 36.9)
Week 7627.4 (22.2 to 32.5)29.2 (23.9 to 34.4)
Week 8028.7 (23.4 to 34.0)31.2 (25.7 to 36.6)
Week 8428.0 (22.8 to 33.1)30.1 (24.6 to 35.5)
Week 8829.1 (23.8 to 34.4)28.4 (23.2 to 33.6)
Week 9227.0 (21.8 to 32.1)29.0 (23.6 to 34.3)
Week 9630.7 (25.3 to 36.0)31.1 (25.5 to 36.6)
Week 10028.6 (23.3 to 33.9)27.2 (22.0 to 32.5)
Week 10427.2 (22.0 to 32.4)30.2 (24.8 to 35.6)
Week 10826.3 (21.1 to 31.4)27.0 (21.7 to 32.4)
Week 11229.4 (24.1 to 34.7)26.5 (21.4 to 31.6)
SecondaryPercentage of Participants With BCVA Snellen Equivalent of 20/40 or Better (BCVA ≥69 Letters) in the Study Eye Averaged Over Weeks 40, 44, and 48

BCVA was measured on the ETDRS chart at a starting distance of 4 meters. The BCVA letter score ranges from 0 to 100 (best score), and a gain in BCVA from baseline indicates an improvement in visual acuity. For each participant, an average BCVA value was calculated across the three visits, and this averaged value was used to determine if the endpoint was met. The results were summarized as the percentage of participants per treatment arm who met the endpoint. The weighted estimates of the percentage of participants were based on the Cochran-Mantel Haenszel (CMH) weights stratified by baseline BCVA (\<69 letters vs. ≥69 letters), baseline LLD (≥33 letters and \<33 letters), and region (U.S. and Canada vs. rest of the world). Treatment policy strategy and hypothetical strategy were applied to non-COVID-19 related and COVID-19 related intercurrent events, respectively. Missing data were not imputed. Invalid BCVA values were excluded. 95% confidence interval (CI) is a rounding of 95.03% CI.

Time frame:
Baseline, average of Weeks 40, 44, and 48
Reported as:
Number · Percentage of participants
Percentage of Participants With BCVA Snellen Equivalent of 20/40 or Better (BCVA ≥69 Letters) in the Study Eye Averaged Over Weeks 40, 44, and 48
Percentage of participantsArm A: FaricimabArm B: Aflibercept
Percentage of Participants With BCVA Snellen Equivalent of 20/40 or Better (BCVA ≥69 Letters) in the Study Eye Averaged Over Weeks 40, 44, and 4855.2 (50.1 to 60.2)49.4 (44.4 to 54.4)
Statistical analysis
  • Arm A: Faricimab vs Arm B: Aflibercept · Difference in cmh weighted percentage: 5.7 · 95% CI -1.4 to 12.9The treatment difference in CMH weighted percentage of participants achieving BCVA ≥69 letters is the calculated difference of Arm A: Faricimab and Arm B: Aflibercept.
SecondaryPercentage of Participants With BCVA Snellen Equivalent of 20/40 or Better (BCVA ≥69 Letters) in the Study Eye Over Time

Best Corrected Visual Acuity (BCVA) was measured on the Early Treatment Diabetic Retinopathy Study (ETDRS) chart at a starting distance of 4 meters. The BCVA letter score ranges from 0 to 100 (best score), and a gain in BCVA letter score from baseline indicates an improvement in visual acuity. The weighted percentage of participants was based on the Cochran-Mantel Haenszel (CMH) weights stratified by baseline BCVA (\<69 letters vs. ≥69 letters), baseline LLD (≥33 letters and \<33 letters), and region (U.S. and Canada vs. rest of the world; Asia and rest of the world were combined). Treatment policy strategy (i.e., all observed values used) and hypothetical strategy (i.e., all values censored after the occurrence of the intercurrent event) were applied to non-COVID-19 related and COVID-19 related intercurrent events, respectively. Missing data were not imputed. Invalid BCVA values were excluded from analysis. 95% confidence interval (CI) is a rounding of 95.03% CI.

Time frame:
Baseline, Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52, 56, 60, 64, 68, 72, 76, 80, 84, 88, 92, 96, 100, 104, 108, and 112
Reported as:
Number · Percentage of participants
Percentage of Participants With BCVA Snellen Equivalent of 20/40 or Better (BCVA ≥69 Letters) in the Study Eye Over Time
Percentage of participantsArm A: FaricimabArm B: Aflibercept
Week 445.7 (41.1 to 50.2)40.1 (35.8 to 44.5)
Week 850.5 (45.8 to 55.1)45.2 (40.7 to 49.7)
Week 1253.5 (48.8 to 58.3)48.5 (43.8 to 53.3)
Week 1656.1 (51.2 to 60.9)47.4 (42.8 to 52.1)
Week 2057.5 (52.6 to 62.4)51.1 (46.3 to 55.9)
Week 2457.4 (52.4 to 62.4)47.8 (42.9 to 52.8)
Week 2855.2 (50.0 to 60.4)48.2 (43.2 to 53.2)
Week 3255.9 (50.8 to 61.1)49.8 (45.0 to 54.6)
Week 3656.0 (50.9 to 61.0)47.4 (42.2 to 52.6)
Week 4054.7 (49.5 to 59.9)52.7 (47.5 to 57.9)
Week 4456.3 (51.4 to 61.3)52.5 (47.3 to 57.7)
Week 4855.0 (49.8 to 60.2)52.3 (47.1 to 57.5)
Week 5255.9 (50.6 to 61.1)55.6 (50.4 to 60.9)
Week 5657.1 (51.8 to 62.3)52.9 (47.7 to 58.2)
Week 6053.0 (47.6 to 58.3)53.6 (48.3 to 58.9)
Week 6458.8 (53.5 to 64.2)52.9 (47.5 to 58.3)
Week 6857.0 (51.7 to 62.4)55.5 (50.0 to 60.9)
Week 7258.1 (52.7 to 63.4)53.3 (48.0 to 58.6)
Week 7658.0 (52.6 to 63.4)54.0 (48.6 to 59.3)
Week 8057.3 (52.0 to 62.6)51.9 (46.5 to 57.4)
Week 8458.4 (53.1 to 63.7)56.9 (51.5 to 62.4)
Week 8857.2 (51.9 to 62.6)51.1 (45.6 to 56.5)
Week 9256.1 (50.8 to 61.4)54.9 (49.5 to 60.3)
Week 9655.5 (49.9 to 61.0)53.9 (48.4 to 59.4)
Week 10055.1 (49.5 to 60.7)51.7 (46.2 to 57.2)
Week 10455.1 (49.4 to 60.7)52.8 (47.3 to 58.2)
Week 10854.8 (49.1 to 60.4)51.0 (45.5 to 56.5)
Week 11255.7 (50.2 to 61.1)51.0 (45.6 to 56.4)
SecondaryPercentage of Participants With BCVA Snellen Equivalent of 20/200 or Worse (BCVA ≤38 Letters) in the Study Eye Averaged Over Weeks 40, 44, and 48

BCVA was measured on the ETDRS chart at a starting distance of 4 meters. The BCVA letter score ranges from 0 to 100 (best score), and a gain in BCVA from baseline indicates an improvement in visual acuity. For each participant, an average BCVA value was calculated across the three visits, and this averaged value was used to determine if the endpoint was met. The results were summarized as the percentage of participants per treatment arm who met the endpoint. The weighted percentage of participants was based on the Cochran-Mantel Haenszel (CMH) weights stratified by baseline BCVA (≥74 letters, 73-55 letters, and ≤54 letters), baseline LLD (≥33 letters and \<33 letters), and region (U.S. and Canada vs. rest of the world). Treatment policy strategy and hypothetical strategy were applied to non-COVID-19 related and COVID-19 related intercurrent events, respectively. Missing data were not imputed. Invalid BCVA values were excluded. 95% confidence interval (CI) is a rounding of 95.03% CI.

Time frame:
Baseline, average of Weeks 40, 44, and 48
Reported as:
Number · Percentage of participants
Percentage of Participants With BCVA Snellen Equivalent of 20/200 or Worse (BCVA ≤38 Letters) in the Study Eye Averaged Over Weeks 40, 44, and 48
Percentage of participantsArm A: FaricimabArm B: Aflibercept
Percentage of Participants With BCVA Snellen Equivalent of 20/200 or Worse (BCVA ≤38 Letters) in the Study Eye Averaged Over Weeks 40, 44, and 487.9 (5.0 to 10.8)7.5 (4.7 to 10.3)
Statistical analysis
  • Arm A: Faricimab vs Arm B: Aflibercept · Difference in cmh weighted percentage: 0.4 · 95% CI -3.6 to 4.4The treatment difference in CMH weighted percentage of participants with BCVA ≤38 letters is the calculated difference of Arm A: Faricimab and Arm B: Aflibercept.
SecondaryPercentage of Participants With BCVA Snellen Equivalent of 20/200 or Worse (BCVA ≤38 Letters) in the Study Eye Over Time

Best Corrected Visual Acuity (BCVA) was measured on the Early Treatment Diabetic Retinopathy Study (ETDRS) chart at a starting distance of 4 meters. The BCVA letter score ranges from 0 to 100 (best score), and a gain in BCVA letter score from baseline indicates an improvement in visual acuity. The weighted percentage of participants was based on the Cochran-Mantel Haenszel (CMH) weights stratified by baseline BCVA (≥74 letters, 73-55 letters, and ≤54 letters), baseline LLD (≥33 letters and \<33 letters), and region (U.S. and Canada vs. rest of the world; Asia and rest of the world were combined). Treatment policy strategy (i.e., all observed values used) and hypothetical strategy (i.e., all values censored after the occurrence of the intercurrent event) were applied to non-COVID-19 related and COVID-19 related intercurrent events, respectively. Missing data were not imputed. Invalid BCVA values were excluded from analysis. 95% confidence interval (CI) is a rounding of 95.03% CI.

Time frame:
Baseline, Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52, 56, 60, 64, 68, 72, 76, 80, 84, 88, 92, 96, 100, 104, 108, and 112
Reported as:
Number · Percentage of participants
Percentage of Participants With BCVA Snellen Equivalent of 20/200 or Worse (BCVA ≤38 Letters) in the Study Eye Over Time
Percentage of participantsArm A: FaricimabArm B: Aflibercept
Week 46.8 (4.3 to 9.4)6.1 (3.7 to 8.5)
Week 87.4 (4.8 to 10.1)6.2 (3.7 to 8.6)
Week 127.6 (5.0 to 10.2)5.9 (3.5 to 8.3)
Week 169.5 (6.6 to 12.5)5.3 (3.0 to 7.6)
Week 209.3 (6.4 to 12.3)5.7 (3.3 to 8.1)
Week 248.1 (5.2 to 11.1)6.3 (3.7 to 8.9)
Week 287.4 (4.6 to 10.3)6.4 (3.7 to 9.1)
Week 328.1 (5.1 to 11.0)6.6 (4.0 to 9.2)
Week 367.8 (4.9 to 10.6)6.8 (4.1 to 9.5)
Week 408.3 (5.3 to 11.3)7.6 (4.8 to 10.3)
Week 447.9 (4.9 to 10.9)6.8 (4.0 to 9.5)
Week 489.7 (6.5 to 12.9)6.3 (3.6 to 9.0)
Week 529.1 (6.0 to 12.2)6.5 (3.7 to 9.2)
Week 568.1 (5.1 to 11.1)6.3 (3.6 to 9.0)
Week 608.2 (5.2 to 11.3)7.3 (4.5 to 10.2)
Week 647.1 (4.2 to 10.1)7.2 (4.3 to 10.1)
Week 688.8 (5.6 to 12.0)6.8 (4.0 to 9.6)
Week 728.4 (5.2 to 11.6)6.2 (3.4 to 8.9)
Week 769.5 (6.2 to 12.9)7.4 (4.5 to 10.3)
Week 809.8 (6.5 to 13.1)8.4 (5.3 to 11.5)
Week 849.3 (6.0 to 12.6)7.2 (4.2 to 10.1)
Week 888.4 (5.2 to 11.6)7.5 (4.5 to 10.4)
Week 928.9 (5.6 to 12.2)9.0 (5.8 to 12.2)
Week 9610.4 (6.8 to 13.9)9.7 (6.5 to 13.0)
Week 10010.3 (6.8 to 13.8)10.9 (7.5 to 14.4)
Week 1049.2 (5.8 to 12.6)9.8 (6.4 to 13.1)
Week 1089.5 (6.0 to 12.9)10.0 (6.5 to 13.4)
Week 1129.0 (5.7 to 12.4)10.6 (7.1 to 14.0)
SecondaryPercentage of Participants in the Faricimab Arm on Once Every 8-Weeks, 12-Weeks, or 16-Weeks Treatment Intervals Among Those Completing Week 48

Percentages are based on the number of participants randomized to the faricimab arm who have not discontinued the study at Week 48. The treatment interval at a given visit is defined as the treatment interval decision followed at that visit. The 95% confidence interval (CI) is a rounding of 95.03% CI.

Time frame:
Week 48
Reported as:
Number · Percentage of participants
Percentage of Participants in the Faricimab Arm on Once Every 8-Weeks, 12-Weeks, or 16-Weeks Treatment Intervals Among Those Completing Week 48
Percentage of participantsArm A: Faricimab
Once Every 8 Weeks22.2 (17.6 to 26.7)
Once Every 12 Weeks32.9 (27.7 to 38.1)
Once Every 16 Weeks44.9 (39.4 to 50.4)
SecondaryPercentage of Participants in the Faricimab Arm on Once Every 8-Weeks, 12-Weeks, or 16-Weeks Treatment Intervals Among Those Completing Week 60

Percentages are based on the number of participants randomized to the faricimab arm who have not discontinued the study at Week 60. The treatment interval at a given visit is defined as the treatment interval decision followed at that visit. The 95% confidence interval (CI) is a rounding of 95.03% CI.

Time frame:
Week 60
Reported as:
Number · Percentage of participants
Percentage of Participants in the Faricimab Arm on Once Every 8-Weeks, 12-Weeks, or 16-Weeks Treatment Intervals Among Those Completing Week 60
Percentage of participantsArm A: Faricimab
Once Every 8 Weeks21.6 (17.0 to 26.3)
Once Every 12 Weeks32.8 (27.5 to 38.1)
Once Every 16 Weeks45.6 (40.0 to 51.2)
SecondaryPercentage of Participants in the Faricimab Arm on Once Every 8-Weeks, 12-Weeks, or 16-Weeks Treatment Intervals Among Those Completing Week 112

Percentages are based on the number of participants randomized to the faricimab arm who have not discontinued the study at Week 112. Treatment interval at a given visit is defined as the treatment interval decision followed at that visit. Treatment interval at Week 112 is calculated using data recorded at Week 108. The 95% confidence interval (CI) is a rounding of 95.03% CI.

Time frame:
Weeks 108 and 112
Reported as:
Number · Percentage of participants
Percentage of Participants in the Faricimab Arm on Once Every 8-Weeks, 12-Weeks, or 16-Weeks Treatment Intervals Among Those Completing Week 112
Percentage of participantsArm A: Faricimab
Once Every 8 Weeks18.8 (14.3 to 23.3)
Once Every 12 Weeks14.3 (10.2 to 18.3)
Once Every 16 Weeks66.9 (61.4 to 72.4)
SecondaryNumber of Study Drug Injections Received in the Study Eye Through Week 48
Time frame:
From Baseline through Week 48
Reported as:
Median · Injections
Number of Study Drug Injections Received in the Study Eye Through Week 48
InjectionsArm A: FaricimabArm B: Aflibercept
Number of Study Drug Injections Received in the Study Eye Through Week 486.0 (1 to 8)8.0 (1 to 8)
SecondaryNumber of Study Drug Injections Received in the Study Eye Through Week 60
Time frame:
From Baseline through Week 60
Reported as:
Median · Injections
Number of Study Drug Injections Received in the Study Eye Through Week 60
InjectionsArm A: FaricimabArm B: Aflibercept
Number of Study Drug Injections Received in the Study Eye Through Week 607.0 (1 to 10)9.0 (1 to 9)
SecondaryNumber of Study Drug Injections Received in the Study Eye Through Week 108
Time frame:
From Baseline through Week 108
Reported as:
Median · Injections
Number of Study Drug Injections Received in the Study Eye Through Week 108
InjectionsArm A: FaricimabArm B: Aflibercept
Number of Study Drug Injections Received in the Study Eye Through Week 10810.0 (1 to 16)15.0 (1 to 15)
SecondaryChange From Baseline in Central Subfield Thickness in the Study Eye Averaged Over Weeks 40, 44, and 48

Central subfield thickness (CST) was defined as the distance between the internal limiting membrane (ILM) and the retinal pigment epithelium (RPE) using optical coherence tomography (OCT), as assessed by the central reading center. For the Mixed Model of Repeated Measures (MMRM) analysis, the model adjusted for treatment group, visit, visit-by-treatment group iteraction, baseline CST (continuous), baseline BCVA (≥74 letters, 73-55 letters, and ≤54 letters), baseline LLD (\<33 letters and ≥33 letters), and region (U.S. and Canada, Asia, and the rest of the world). An unstructured covariance structure was used. Treatment policy strategy (i.e., all observed values used) and hypothetical strategy (i.e., all values censored after the occurrence of the intercurrent event) were applied to non-COVID-19 related and COVID-19 related intercurrent events, respectively. Missing data were implicitly imputed by MMRM. 95% confidence interval (CI) is a rounding of 95.03% CI.

Time frame:
From Baseline through Week 48
Reported as:
Mean · microns
Change From Baseline in Central Subfield Thickness in the Study Eye Averaged Over Weeks 40, 44, and 48
micronsArm A: FaricimabArm B: Aflibercept
Change From Baseline in Central Subfield Thickness in the Study Eye Averaged Over Weeks 40, 44, and 48-137.1 (-143.1 to -131.2)-130.8 (-136.8 to -124.8)
Statistical analysis
  • Arm A: Faricimab vs Arm B: Aflibercept · Adjusted mean difference: -6.4 · 95% CI -14.8 to 2.1The treatment difference in adjusted means of change from baseline CST is the calculated difference of Arm A: Faricimab and Arm B: Aflibercept. MMRM adjustments are listed in the outcome measure description.
SecondaryChange From Baseline in Central Subfield Thickness in the Study Eye Averaged Over Weeks 52, 56, and 60

Central subfield thickness (CST) was defined as the distance between the internal limiting membrane (ILM) and the retinal pigment epithelium (RPE) using optical coherence tomography (OCT), as assessed by the central reading center. For the Mixed Model of Repeated Measures (MMRM) analysis, the model adjusted for treatment group, visit, visit-by-treatment group interaction, baseline CST (continuous), baseline BCVA (≥74 letters, 73-55 letters, and ≤54 letters), baseline LLD (\<33 letters and ≥33 letters), and region (U.S. and Canada, Asia, and the rest of the world). An unstructured covariance structure was used. Treatment policy strategy (i.e., all observed values used) and hypothetical strategy (i.e., all values censored after the occurrence of the intercurrent event) were applied to non-COVID-19 related and COVID-19 related intercurrent events, respectively. Missing data were implicitly imputed by MMRM. 95% confidence interval (CI) is a rounding of 95.03% CI.

Time frame:
From Baseline through Week 60
Reported as:
Mean · microns
Change From Baseline in Central Subfield Thickness in the Study Eye Averaged Over Weeks 52, 56, and 60
micronsArm A: FaricimabArm B: Aflibercept
Change From Baseline in Central Subfield Thickness in the Study Eye Averaged Over Weeks 52, 56, and 60-135.7 (-141.2 to -130.1)-137.0 (-142.7 to -131.3)
Statistical analysis
  • Arm A: Faricimab vs Arm B: Aflibercept · Adjusted mean difference: 1.4 · 95% CI -6.6 to 9.3The treatment difference in adjusted means of change from baseline CST is the calculated difference of Arm A: Faricimab and Arm B: Aflibercept. MMRM adjustments are listed in the outcome measure description.
SecondaryChange From Baseline in Central Subfield Thickness in the Study Eye Over Time

Central subfield thickness (CST) was defined as the distance between the internal limiting membrane (ILM) and the retinal pigment epithelium (RPE) using optical coherence tomography (OCT), as assessed by the central reading center. For the Mixed Model of Repeated Measures (MMRM) analysis, the model adjusted for treatment group, visit, visit-by-treatment group interaction, baseline CST (continuous), baseline BCVA (≥74 letters, 73-55 letters, and ≤54 letters), baseline LLD (\<33 letters and ≥33 letters), and region (U.S. and Canada, Asia, and the rest of the world). An unstructured covariance structure was used. Treatment policy strategy (i.e., all observed values used) and hypothetical strategy (i.e., all values censored after the occurrence of the intercurrent event) were applied to non-COVID-19 related and COVID-19 related intercurrent events, respectively. Missing data were implicitly imputed by MMRM. 95% confidence interval (CI) is a rounding of 95.03% CI.

Time frame:
Baseline, Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52, 56, 60, 64, 68, 72, 76, 80, 84, 88, 92, 96, 100, 104, 108, and 112
Reported as:
Mean · microns
Change From Baseline in Central Subfield Thickness in the Study Eye Over Time
micronsArm A: FaricimabArm B: Aflibercept
Week 4-126.5 (-132.3 to -120.6)-113.9 (-119.8 to -108.0)
Week 8-138.0 (-143.7 to -132.3)-123.8 (-129.6 to -118.0)
Week 12-141.7 (-147.1 to -136.3)-129.6 (-135.0 to -124.1)
Week 16-143.7 (-150.3 to -137.1)-112.9 (-119.6 to -106.2)
Week 20-130.9 (-136.8 to -125.0)-132.9 (-138.8 to -126.9)
Week 24-130.1 (-137.1 to -123.1)-112.2 (-119.3 to -105.2)
Week 28-127.3 (-134.0 to -120.6)-130.1 (-136.9 to -123.3)
Week 32-138.6 (-145.8 to -131.5)-115.3 (-122.5 to -108.1)
Week 36-124.6 (-131.3 to -118.0)-135.2 (-141.9 to -128.5)
Week 40-142.5 (-149.3 to -135.6)-122.5 (-129.4 to -115.6)
Week 44-130.9 (-136.7 to -125.1)-141.6 (-147.6 to -135.7)
Week 48-135.5 (-142.3 to -128.6)-123.9 (-130.8 to -117.0)
Week 52-140.9 (-146.4 to -135.3)-139.6 (-145.3 to -134.0)
Week 56-138.9 (-145.7 to -132.1)-125.6 (-132.5 to -118.6)
Week 60-125.9 (-132.0 to -119.7)-142.3 (-148.6 to -136.1)
Week 64-143.8 (-150.3 to -137.2)-126.0 (-132.7 to -119.3)
Week 68-138.0 (-143.9 to -132.2)-138.8 (-144.8 to -132.8)
Week 72-140.7 (-147.3 to -134.1)-128.8 (-135.5 to -122.0)
Week 76-136.1 (-142.4 to -129.7)-139.0 (-145.4 to -132.6)
Week 80-144.4 (-151.1 to -137.8)-128.7 (-135.5 to -121.9)
Week 84-143.5 (-149.2 to -137.8)-143.2 (-149.1 to -137.4)
Week 88-145.5 (-151.6 to -139.5)-133.3 (-139.5 to -127.1)
Week 92-142.1 (-148.0 to -136.1)-143.2 (-149.3 to -137.1)
Week 96-146.8 (-153.1 to -140.4)-134.7 (-141.2 to -128.2)
Week 100-145.0 (-151.7 to -138.3)-146.2 (-153.1 to -139.3)
Week 104-149.6 (-156.3 to -142.8)-137.4 (-144.3 to -130.5)
Week 108-148.5 (-154.4 to -142.6)-148.3 (-154.4 to -142.2)
Week 112-152.9 (-159.2 to -146.7)-139.1 (-145.5 to -132.7)
SecondaryPercentage of Participants With Absence of Intraretinal Fluid in the Study Eye Over Time

Intraretinal fluid was measured using optical coherence tomography (OCT) in the central subfield (center 1 millimetre \[mm\]). The weighted estimates of the percentage of participants with absence of intraretinal fluid were based on the Cochran-Mantel Haenszel (CMH) weights stratified by baseline BCVA (≥74 letters, 73-55 letters, and ≤54 letters), baseline LLD (≥33 letters and \<33 letters), and region (U.S. and Canada vs. rest of the world). Asia and rest of the world regions were combined due to a small number of enrolled participants. Treatment policy strategy (i.e., all observed values used) and hypothetical strategy (i.e., all values censored after the occurrence of the intercurrent event) were applied to non-COVID-19 related and COVID-19 related intercurrent events, respectively. Missing data were not imputed. 95% confidence interval (CI) is a rounding of 95.03% CI.

Time frame:
Baseline, Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52, 56, 60, 104, 108, and 112
Reported as:
Number · Percentage of participants
Percentage of Participants With Absence of Intraretinal Fluid in the Study Eye Over Time
Percentage of participantsArm A: FaricimabArm B: Aflibercept
Week 486.9 (83.5 to 90.4)82.9 (78.9 to 87.0)
Week 888.5 (85.2 to 91.9)84.6 (80.7 to 88.5)
Week 1287.5 (84.0 to 91.0)84.5 (80.6 to 88.5)
Week 1690.6 (87.5 to 93.7)76.5 (71.9 to 81.0)
Week 2078.8 (74.5 to 83.0)86.1 (82.3 to 89.8)
Week 2478.7 (74.2 to 83.1)78.0 (73.4 to 82.7)
Week 2877.1 (72.4 to 81.8)85.9 (81.8 to 89.9)
Week 3286.3 (82.5 to 90.2)78.3 (73.6 to 82.9)
Week 3679.6 (75.0 to 84.1)86.1 (82.1 to 90.1)
Week 4084.5 (80.3 to 88.7)77.5 (72.7 to 82.3)
Week 4478.5 (73.7 to 83.2)84.2 (79.9 to 88.5)
Week 4884.1 (79.8 to 88.4)77.7 (72.8 to 82.5)
Week 5285.9 (81.9 to 89.8)85.3 (81.1 to 89.4)
Week 5685.2 (81.1 to 89.2)81.1 (76.6 to 85.6)
Week 6077.8 (73.0 to 82.6)85.4 (81.2 to 89.5)
Week 10486.0 (81.9 to 90.1)80.0 (75.1 to 84.9)
Week 10882.2 (77.7 to 86.6)83.5 (79.0 to 88.1)
Week 11285.9 (81.8 to 90.0)80.5 (75.7 to 85.4)
SecondaryPercentage of Participants With Absence of Subretinal Fluid in the Study Eye Over Time

Subretinal fluid was measured using optical coherence tomography (OCT) in the central subfield (center 1 mm). The weighted estimates of the percentage of participants with absence of subretinal fluid were based on the Cochran-Mantel Haenszel (CMH) weights stratified by baseline BCVA (≥74 letters, 73-55 letters, and ≤54 letters), baseline LLD (≥33 letters and \<33 letters), and region (U.S. and Canada vs. rest of the world). Asia and rest of the world regions were combined due to a small number of enrolled participants. Treatment policy strategy (i.e., all observed values used) and hypothetical strategy (i.e., all values censored after the occurrence of the intercurrent event) were applied to non-COVID-19 related and COVID-19 related intercurrent events, respectively. Missing data were not imputed. 95% confidence interval (CI) is a rounding of 95.03% CI.

Time frame:
Baseline, Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52, 56, 60, 104, 108, and 112
Reported as:
Number · Percentage of participants
Percentage of Participants With Absence of Subretinal Fluid in the Study Eye Over Time
Percentage of participantsArm A: FaricimabArm B: Aflibercept
Week 470.9 (66.1 to 75.7)61.7 (56.4 to 66.9)
Week 879.8 (75.6 to 84.1)73.6 (68.9 to 78.4)
Week 1288.6 (85.1 to 92.0)79.6 (75.3 to 84.0)
Week 1690.6 (87.4 to 93.8)63.8 (58.6 to 68.9)
Week 2076.1 (71.6 to 80.7)80.4 (76.1 to 84.8)
Week 2473.7 (68.8 to 78.5)59.1 (53.5 to 64.6)
Week 2871.5 (66.6 to 76.4)78.7 (73.9 to 83.5)
Week 3282.6 (78.3 to 87.0)62.2 (56.7 to 67.7)
Week 3670.6 (65.5 to 75.7)80.7 (76.1 to 85.2)
Week 4077.6 (72.9 to 82.3)63.9 (58.4 to 69.5)
Week 4465.7 (60.3 to 71.0)76.2 (71.1 to 81.2)
Week 4872.5 (67.5 to 77.5)62.1 (56.5 to 67.7)
Week 5283.0 (78.8 to 87.3)80.6 (76.0 to 85.3)
Week 5680.7 (76.3 to 85.2)71.6 (66.4 to 76.8)
Week 6063.6 (58.1 to 69.0)80.0 (75.3 to 84.8)
Week 10480.0 (75.3 to 84.7)73.9 (68.5 to 79.3)
Week 10876.1 (71.2 to 81.0)80.7 (75.8 to 85.5)
Week 11280.9 (76.4 to 85.4)77.5 (72.4 to 82.6)
SecondaryPercentage of Participants With Absence of Intraretinal Fluid and Subretinal Fluid in the Study Eye Over Time

Intraretinal fluid and subretinal fluid were measured using optical coherence tomography (OCT) in the central subfield (center 1 mm). The weighted estimates of the percentage of participants with absence of intraretinal and subretinal fluid were based on the Cochran-Mantel Haenszel (CMH) weights stratified by baseline BCVA (≥74 letters, 73-55 letters, and ≤54 letters), baseline LLD (≥33 letters and \<33 letters), and region (U.S. and Canada vs. rest of the world). Asia and rest of the world regions were combined due to a small number of enrolled participants. Treatment policy strategy (i.e., all observed values used) and hypothetical strategy (i.e., all values censored after the occurrence of the intercurrent event) were applied to non-COVID-19 related and COVID-19 related intercurrent events, respectively. Missing data were not imputed. 95% confidence interval (CI) is a rounding of 95.03% CI.

Time frame:
Baseline, Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52, 56, 60, 104, 108, and 112
Reported as:
Number · Percentage of participants
Percentage of Participants With Absence of Intraretinal Fluid and Subretinal Fluid in the Study Eye Over Time
Percentage of participantsArm A: FaricimabArm B: Aflibercept
Week 459.5 (54.2 to 64.8)49.8 (44.4 to 55.2)
Week 870.2 (65.2 to 75.1)61.6 (56.3 to 66.9)
Week 1277.0 (72.4 to 81.5)66.6 (61.5 to 71.7)
Week 1682.4 (78.3 to 86.5)47.6 (42.2 to 53.0)
Week 2062.3 (57.3 to 67.4)68.6 (63.6 to 73.7)
Week 2456.5 (50.8 to 62.1)45.4 (39.7 to 51.1)
Week 2855.5 (49.9 to 61.1)66.5 (61.0 to 72.0)
Week 3273.1 (68.0 to 78.1)48.6 (42.9 to 54.3)
Week 3656.3 (50.8 to 61.9)68.3 (62.9 to 73.7)
Week 4065.8 (60.3 to 71.2)49.0 (43.2 to 54.8)
Week 4449.5 (43.7 to 55.3)64.3 (58.5 to 70.0)
Week 4862.2 (56.6 to 67.8)46.1 (40.3 to 52.0)
Week 5270.3 (65.2 to 75.5)68.8 (63.4 to 74.3)
Week 5666.9 (61.5 to 72.3)57.5 (51.8 to 63.3)
Week 6049.3 (43.5 to 55.0)69.1 (63.6 to 74.6)
Week 10468.1 (62.5 to 73.7)58.6 (52.7 to 64.6)
Week 10861.6 (55.9 to 67.3)67.1 (61.3 to 72.9)
Week 11268.7 (63.3 to 74.1)61.1 (55.1 to 67.1)
SecondaryPercentage of Participants With Absence of Pigment Epithelial Detachment in the Study Eye Over Time

Pigment epithelial detachment was measured using optical coherence tomography (OCT) in the central subfield (center 1 mm). The weighted estimates of the percentage of participants with absence of pigment epithelial detachment were based on the Cochran-Mantel Haenszel (CMH) weights stratified by baseline BCVA (≥74 letters, 73-55 letters, and ≤54 letters), baseline LLD (≥33 letters and \<33 letters), and region (U.S. and Canada vs. rest of the world). Asia and rest of the world regions were combined due to a small number of enrolled participants. Treatment policy strategy (i.e., all observed values used) and hypothetical strategy (i.e., all values censored after the occurrence of the intercurrent event) were applied to non-COVID-19 related and COVID-19 related intercurrent events, respectively. Missing data were not imputed. 95% confidence interval (CI) is a rounding of 95.03% CI.

Time frame:
Baseline, Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52, 56, 60, 104, 108, and 112
Reported as:
Number · Percentage of participants
Percentage of Participants With Absence of Pigment Epithelial Detachment in the Study Eye Over Time
Percentage of participantsArm A: FaricimabArm B: Aflibercept
Week 43.7 (1.7 to 5.8)5.6 (3.1 to 8.1)
Week 83.1 (1.3 to 5.0)4.1 (1.9 to 6.2)
Week 124.7 (2.4 to 7.0)5.5 (3.0 to 8.0)
Week 162.5 (0.8 to 4.1)5.8 (3.2 to 8.4)
Week 203.8 (1.7 to 5.9)6.0 (3.4 to 8.6)
Week 244.1 (1.8 to 6.3)4.9 (2.5 to 7.4)
Week 282.6 (0.9 to 4.4)1.9 (0.3 to 3.5)
Week 324.3 (2.0 to 6.6)1.8 (0.3 to 3.3)
Week 364.8 (2.4 to 7.1)3.9 (1.7 to 6.1)
Week 406.3 (3.5 to 9.0)7.3 (4.4 to 10.3)
Week 443.9 (1.7 to 6.2)9.1 (5.9 to 12.4)
Week 483.3 (1.2 to 5.3)6.5 (3.7 to 9.3)
Week 525.8 (3.1 to 8.5)8.1 (5.0 to 11.3)
Week 564.7 (2.3 to 7.2)5.2 (2.7 to 7.7)
Week 603.5 (1.4 to 5.6)6.3 (3.4 to 9.1)
Week 1048.0 (4.8 to 11.2)8.3 (5.0 to 11.7)
Week 1086.9 (3.9 to 10.0)8.0 (4.7 to 11.2)
Week 1128.1 (4.9 to 11.3)12.5 (8.4 to 16.5)
SecondaryPercentage of Participants With Absence of Intraretinal Cysts in the Study Eye Over Time
Time frame:
Up to 112 weeks

No measurements were reported for this outcome.

SecondaryChange From Baseline in Total Area of Choroidal Neovascularization Lesion in the Study Eye at Week 48

The total area of the choroidal neovascularization lesion in the study eye was evaluated by a central reading center using fundus fluorescein angiography (FFA). Assessments were censored following COVID-19 related intercurrent events. Baseline was defined as the last available measurement obtained on or prior to randomization.

Time frame:
Baseline and Week 48
Reported as:
Mean · millimetres squared (mm^2)
Change From Baseline in Total Area of Choroidal Neovascularization Lesion in the Study Eye at Week 48
millimetres squared (mm^2)Arm A: FaricimabArm B: Aflibercept
Change From Baseline in Total Area of Choroidal Neovascularization Lesion in the Study Eye at Week 480.3 ± 4.61.1 ± 4.4
SecondaryChange From Baseline in Total Area of Choroidal Neovascularization Lesion in the Study Eye at Week 112

The total area of the choroidal neovascularization lesion in the study eye was evaluated by a central reading center using fundus fluorescein angiography (FFA). Assessments were censored following COVID-19 related intercurrent events. Baseline was defined as the last available measurement obtained on or prior to randomization.

Time frame:
Baseline and Week 112
Reported as:
Mean · millimetres squared (mm^2)
Change From Baseline in Total Area of Choroidal Neovascularization Lesion in the Study Eye at Week 112
millimetres squared (mm^2)Arm A: FaricimabArm B: Aflibercept
Change From Baseline in Total Area of Choroidal Neovascularization Lesion in the Study Eye at Week 1121.7 ± 7.51.7 ± 4.2
SecondaryChange From Baseline in Total Area of Choroidal Neovascularization Leakage in the Study Eye at Week 48

The total area of choroidal neovascularization leakage in the study eye was evaluated by a central reading center using fundus fluorescein angiography (FFA). Assessments were censored following COVID-19 related intercurrent events. Baseline was defined as the last available measurement obtained on or prior to randomization.

Time frame:
Baseline and Week 48
Reported as:
Mean · millimetres squared (mm^2)
Change From Baseline in Total Area of Choroidal Neovascularization Leakage in the Study Eye at Week 48
millimetres squared (mm^2)Arm A: FaricimabArm B: Aflibercept
Change From Baseline in Total Area of Choroidal Neovascularization Leakage in the Study Eye at Week 48-3.3 ± 6.6-2.1 ± 6.3
SecondaryChange From Baseline in Total Area of Choroidal Neovascularization Leakage in the Study Eye at Week 112

The total area of choroidal neovascularization leakage in the study eye was evaluated by a central reading center using fundus fluorescein angiography (FFA). Assessments were censored following COVID-19 related intercurrent events. Baseline was defined as the last available measurement obtained on or prior to randomization.

Time frame:
Baseline and Week 112
Reported as:
Mean · millimetres squared (mm^2)
Change From Baseline in Total Area of Choroidal Neovascularization Leakage in the Study Eye at Week 112
millimetres squared (mm^2)Arm A: FaricimabArm B: Aflibercept
Change From Baseline in Total Area of Choroidal Neovascularization Leakage in the Study Eye at Week 112-5.3 ± 7.2-4.2 ± 5.9
SecondaryPercentage of Participants With at Least One Adverse Event

This analysis of adverse events (AEs) includes both ocular and non-ocular (systemic) AEs. Multiple occurrences of the same AE in one individual are counted only once. Investigators sought information on AEs at each contact with the participants. All AEs were recorded and the investigator made an assessment of seriousness, severity, and causality of each AE. AEs of special interest included the following: Cases of potential drug-induced liver injury that include an elevated ALT or AST in combination with either an elevated bilirubin or clinical jaundice, as defined by Hy's Law; Suspected transmission of an infectious agent by the study drug; Sight-threatening AEs that cause a drop in visual acuity (VA) score ≥30 letters lasting more than 1 hour, require surgical or medical intervention to prevent permanent loss of sight, or are associated with severe intraocular inflammation (IOI).

Time frame:
From first dose of study drug through end of study (up to 112 weeks)
Reported as:
Number · Percentage of participants
Percentage of Participants With at Least One Adverse Event
Percentage of participantsArm A: FaricimabArm B: Aflibercept
Adverse Event (AE)84.988.0
Serious AE (SAE)27.531.0
AE Leading to Withdrawal from Study Treatment4.82.8
AE of Special Interest (AESI)7.36.1
SecondaryPercentage of Participants With at Least One Ocular Adverse Event in the Study Eye or the Fellow Eye

This analysis of adverse events (AEs) only includes ocular AEs, which are categorized as having occurred either in the study eye or the fellow eye. Multiple occurrences of the same AE in one individual are counted only once. Investigators sought information on AEs at each contact with the participants. All AEs were recorded and the investigator made an assessment of seriousness, severity, and causality of each AE. Ocular AEs of special interest included the following: Suspected transmission of an infectious agent by the study drug; Sight-threatening AEs that cause a drop in visual acuity (VA) score ≥30 letters lasting more than 1 hour, require surgical or medical intervention to prevent permanent loss of sight, or are associated with severe intraocular inflammation (IOI).

Time frame:
From first dose of study drug through end of study (up to 112 weeks)
Reported as:
Number · Percentage of participants
Percentage of Participants With at Least One Ocular Adverse Event in the Study Eye or the Fellow Eye
Percentage of participantsArm A: FaricimabArm B: Aflibercept
Study Eye: Adverse Event (AE)52.947.5
Study Eye: Serious AE (SAE)4.54.9
Study Eye: AE Leading to Withdrawal from Treatment3.31.8
Study Eye: Treatment-related AE3.63.1
Study Eye: Treatment-related SAE1.80.6
Study Eye: AE of Special Interest (AESI)3.94.3
Study Eye: AESI, Drop in VA Score ≥30 Letters2.73.1
Study Eye: AESI, Associated with Severe IOI0.60.3
Study Eye: AESI, Intervention Req. to Prevent Permanent Vision Loss0.60.9
Study Eye: Suspected Transmission of Infectious Agent by Study Drug0.00.3
Fellow Eye: AE46.241.7
Fellow Eye: SAE3.62.5
Fellow Eye: AESI3.02.1
Fellow Eye: AESI, Drop in VA Score ≥30 Letters2.11.8
Fellow Eye: AESI, Intervention Req. to Prevent Permanent Vision Loss0.90.3
SecondaryPercentage of Participants With at Least One Non-Ocular Adverse Event

This analysis of adverse events (AEs) only includes non-ocular (systemic) AEs. Multiple occurrences of the same AE in one individual are counted only once. Investigators sought information on AEs at each contact with the participants. All AEs were recorded and the investigator made an assessment of seriousness, severity, and causality of each AE. The non-ocular AE of special interest was: Cases of potential drug-induced liver injury that include an elevated ALT or AST in combination with either an elevated bilirubin or clinical jaundice, as defined by Hy's Law.

Time frame:
From first dose of study drug through end of study (up to 112 weeks)
Reported as:
Number · Percentage of participants
Percentage of Participants With at Least One Non-Ocular Adverse Event
Percentage of participantsArm A: FaricimabArm B: Aflibercept
Adverse Event (AE)71.075.8
Serious AE (SAE)21.826.4
AE Leading to Withdrawal from Study Treatment1.50.9
AE of Special Interest (AESI)0.30.0
SecondaryPlasma Concentration of Faricimab Over Time

Faricimab concentration in plasma was determined using a validated immunoassay method.

Time frame:
Pre-dose at Baseline, Weeks 4, 16, 20, 48, 76, and 112
Reported as:
Mean · micrograms per millilitre (μg/mL)
Plasma Concentration of Faricimab Over Time
micrograms per millilitre (μg/mL)Arm A: Faricimab
Baseline0.0000 ± 0.0001
Week 40.0287 ± 0.0209
Week 160.0333 ± 0.0250
Week 200.0046 ± 0.0051
Week 480.0149 ± 0.0185
Week 760.0053 ± 0.0117
Week 1120.0119 ± 0.0149
SecondaryPercentage of Participants Who Tested Positive for Treatment-Emergent Anti-Drug Antibodies Against Faricimab During the Study

Anti-drug antibodies (ADAs) against fariciamb were detected in plasma using a validated bridging enzyme-linked immunosorbent assay (ELISA). The percentage of participants with treatment-emergent ADA-positive samples includes post-baseline evaluable participants with at least one treatment-induced (defined as having an ADA-negative sample or missing sample at baseline and any positive post-baseline sample) or treatment-boosted (defined as having an ADA-positive sample at baseline and any positive post-baseline sample with a titer that is equal to or greater than 4-fold baseline titer) ADA-positive sample during the study treatment period.

Time frame:
Pre-dose at Baseline, Weeks 4, 20, 48, 76, and 112
Reported as:
Number · Percentage of participants
Percentage of Participants Who Tested Positive for Treatment-Emergent Anti-Drug Antibodies Against Faricimab During the Study
Percentage of participantsArm A: Faricimab
Total Treatment-Emergent ADA-Positive16.1
Treatment-Induced ADA-Positive16.1
Treatment-Boosted ADA-Positive0.0

Adverse events

Collected over From first dose of study drug through end of study (up to 112 weeks). Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Arm A: Faricimab10/331 (3%)91/331 (27.5%)178/331 (53.8%)
Arm B: Aflibercept14/326 (4.3%)101/326 (31%)165/326 (50.6%)
Most frequent serious events
Showing 10 of 198
Most frequent serious events
EventArm A: FaricimabArm B: Aflibercept
Neovascular age-related macular degenerationEye disorders8/3314/326
COVID-19 pneumoniaInfections and infestations2/3317/326
Cardiac failure congestiveCardiac disorders3/3316/326
PneumoniaInfections and infestations2/3316/326
SepsisInfections and infestations0/3315/326
Cerebrovascular accidentNervous system disorders2/3315/326
COVID-19Infections and infestations3/3314/326
DyspnoeaRespiratory, thoracic and mediastinal disorders1/3314/326
OsteoarthritisMusculoskeletal and connective tissue disorders4/3312/326
Atrial fibrillationCardiac disorders3/3313/326
Most frequent other events
Most frequent other events
EventArm A: FaricimabArm B: Aflibercept
Neovascular age-related macular degenerationEye disorders80/33162/326
CataractEye disorders38/33126/326
Conjunctival haemorrhageEye disorders35/33137/326
Urinary tract infectionInfections and infestations19/33129/326
NasopharyngitisInfections and infestations27/33122/326
FallInjury, poisoning and procedural complications18/33122/326
Vitreous detachmentEye disorders22/33121/326
Dry eyeEye disorders15/33121/326
Posterior capsule opacificationEye disorders15/33119/326
HypertensionVascular disorders15/33118/326

Baseline characteristics

Intent-to-Treat (ITT) Population: all participants who were randomized in the study, grouped according to the treatment assigned at randomization.

Age, Continuous
Age, Continuous(Years)Arm A: FaricimabArm B: AfliberceptTotal
Mean74.8 ± 8.476.1 ± 8.675.5 ± 8.5
Sex: Female, Male
Sex: Female, Male(Participants)Arm A: FaricimabArm B: AfliberceptTotal
Female203188391
Male128139267
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Arm A: FaricimabArm B: AfliberceptTotal
Hispanic or Latino354681
Not Hispanic or Latino287274561
Unknown or Not Reported9716
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Arm A: FaricimabArm B: AfliberceptTotal
White278270548
Asian383472
Unknown121729
Black or African American257
American Indian or Alaska Native101
Multiple011
Region of Enrollment
Region of Enrollment(Participants)Arm A: FaricimabArm B: AfliberceptTotal
United States and Canada135132267
Asia353368
Rest of the World161162323
Number of Participants by the Eye (Right or Left) Chosen as the Study Eye
Number of Participants by the Eye (Right or Left) Chosen as the Study Eye(Participants)Arm A: FaricimabArm B: AfliberceptTotal
Right Eye168170338
Left Eye163157320
Best Corrected Visual Acuity (BCVA) Letter Score in the Study Eye
Best Corrected Visual Acuity (BCVA) Letter Score in the Study Eye(ETDRS Letters)Arm A: FaricimabArm B: AfliberceptTotal
Mean58.7 ± 14.058.9 ± 13.358.8 ± 13.6
Number of Participants by the BCVA Letter Score Categories in the Study Eye
Number of Participants by the BCVA Letter Score Categories in the Study Eye(Participants)Arm A: FaricimabArm B: AfliberceptTotal
≥74 Letters453984
73 to 55 Letters181183364
≤54 Letters105105210

2 further baseline measures are reported on the registry.

08

Study locations

137 sites
  • Associated Retina Consultants
    Phoenix, Arizona 85020, United States
  • Arizona Retina and Vitreous Consultants
    Phoenix, Arizona 85021, United States
  • Northern California Retina Vitreous Associates
    Mountain View, California 94040, United States
  • Retinal Consultants Med Group
    Sacramento, California 95825, United States
  • Orange County Retina Med Group
    Santa Ana, California 92705, United States
  • California Retina Consultants
    Santa Barbara, California 93103, United States
  • Colorado Retina Associates, PC
    Golden, Colorado 80401, United States
  • Retina Group of Florida
    Fort Lauderdale, Florida 33308, United States
  • Retina Care Specialists
    Palm Beach Gardens, Florida 33410, United States
  • Southern Vitreoretinal Assoc
    Tallahassee, Florida 32308, United States
  • Retina Associates of Florida, LLC
    Tampa, Florida 33609, United States
  • Southeast Retina Center
    Augusta, Georgia 30909, United States
  • Georgia Retina PC
    Marietta, Georgia 30060, United States
  • Retina Consultants of Hawaii
    ‘Aiea, Hawaii 96701, United States
  • University Retina and Macula Associates, PC
    Oak Forest, Illinois 60452, United States
  • Prairie Retina Center
    Springfield, Illinois 62704, United States
  • Raj K. Maturi, MD PC
    Indianapolis, Indiana 46290, United States
  • Wolfe Eye Clinic
    West Des Moines, Iowa 50266, United States
  • Maine Eye Center
    Portland, Maine 04101, United States
  • The Retina Care Center
    Baltimore, Maryland 21209, United States
  • Cumberland Valley Retina PC
    Hagerstown, Maryland 21740, United States
  • Retina Specialists
    Towson, Maryland 21204, United States
  • Ophthalmic Consultants of Boston
    Boston, Massachusetts 02114, United States
  • VitreoRetinal Surgery, PLLC.
    Minneapolis, Minnesota 55435, United States
  • Mid Atlantic Retina - Wills Eye Hospital
    Cherry Hill, New Jersey 08034, United States
  • Island Retina
    Shirley, New York 11967, United States
  • Retina Assoc of Cleveland Inc
    Cleveland, Ohio 44122, United States
  • The Ohio State University Havener Eye Institute
    Columbus, Ohio 43212, United States
  • Midwest Retina
    Dublin, Ohio 43016, United States
  • Palmetto Retina Center
    West Columbia, South Carolina 29169, United States
  • Southeastern Retina Associates Chattanooga
    Chattanooga, Tennessee 37421, United States
  • Retina Res Institute of Texas
    Abilene, Texas 79606, United States
  • Austin Retina Associates
    Austin, Texas 78705, United States
  • Austin Clinical Research LLC
    Austin, Texas 78750, United States
  • Retina Center of Texas
    Grapevine, Texas 76051, United States
  • Retina Consultants of Houston
    The Woodlands, Texas 77384, United States
  • Strategic Clinical Research Group, LLC
    Willow Park, Texas 76087, United States
  • Retina Associates of Utah, PLLC
    Murray, Utah 84107, United States
  • Piedmont Eye Center
    Lynchburg, Virginia 24502, United States
  • Wagner Kapoor Institute
    Norfolk, Virginia 23502, United States
  • Pacific Northwest Retina
    Silverdale, Washington 98383, United States
  • Organizacion Medica de Investigacion
    Buenos Aires, C1015ABO, Argentina
  • Fundacion Zambrano
    CABA, 1023, Argentina
  • Centro Oftalmológico Dr. Charles S.A.
    Capital Federal, C1116, Argentina
  • Oftalmos
    Capital Federal, C1120AAN, Argentina
  • Buenos Aires Mácula
    Ciudad Autonoma Buenos Aires, C1061AAE, Argentina
  • Oftar
    Mendoza, M5500GGK, Argentina
  • Grupo Laser Vision
    Rosario, S2000DLA, Argentina
  • Eyeclinic Albury Wodonga
    Albury, New South Wales 2640, Australia
  • Marsden Eye Research Centre
    Parramatta, New South Wales 2150, Australia
  • Strathfield Retina Clinic
    Strathfield, New South Wales 2135, Australia
  • Sydney Eye Hospital
    Sydney, New South Wales 2000, Australia
  • Sydney Retina Clinic and Day Surgery
    Sydney, New South Wales 2000, Australia
  • Sydney West Retina
    Westmead, New South Wales 2145, Australia
  • Centre For Eye Research Australia
    East Melbourne, Victoria 3002, Australia
  • Retina Specialists Victoria
    Rowville, Victoria 3178, Australia
  • The Lions Eye Institute
    Nedlands, Western Australia 6009, Australia
  • LKH-Univ.Klinikum Graz
    Graz, 8036, Austria
  • Medizinische Universität Wien
    Vienna, 1090, Austria
  • Hospital de Olhos de Aparecida - HOA
    Aparecida de Goiânia, Goiás 74980-010, Brazil
  • Universidade Federal de Sao Paulo - UNIFESP*X
    São Paulo, São Paulo 04023-062, Brazil
  • Specialized Hospital for Active Treatment of Eye Diseases Zora
    Sofia, 1233, Bulgaria
  • Pentagram Eye Hospital (Medical Center "Pentagram")
    Sofia, 1309, Bulgaria
  • Beijing Friendship Hospital
    Beijing, 100050, China
  • Beijing Tongren Hospital
    Beijing, 100730, China
  • Peking Union Medical College Hospital
    Beijing, 100730, China
  • The Second Hospital of Jilin University
    Changchun, 130041, China
  • West China Hospital, Sichuan University
    Chengdu, 610041, China
  • Southwest Hospital , Third Military Medical University
    Chongqing, 400014, China
  • Army Medical Center of PLA(Daping Hospital)
    Chongqing, 400042, China
  • Zhongshan Ophthalmic Center, Sun Yat-sen University
    Guangzhou, 510060, China
  • The Second Affiliated Hospital of Harbin Medical University
    Harbin, 150081, China
  • The Affiliated Eye Hospital of Nanjing Medical University
    Nanjing, 210029, China
  • Shanghai First People's Hospital
    Shanghai, 200080, China
  • He Eye Specialist Shenyang Hospital
    Shenyang, 110034, China
  • Tianjin Eye Hospital
    Tianjin, 300050, China
  • Eye Hospital, Wenzhou Medical University
    Wenzhou, 325027, China
  • Wuxi No.2 People's Hospital
    Wuxi, 214000, China
  • Rigshospitalet Glostrup
    Glostrup Municipality, 2600, Denmark
  • Sjællands Universitetshospital, Roskilde
    Roskilde, 4000, Denmark
  • Chi De Creteil
    Créteil, 94010, France
  • Pole Vision Val d'Ouest
    Écully, 69130, France
  • Hopital de la croix rousse
    Lyon, 69317, France
  • Centre Paradis Monticelli
    Marseille, 13008, France
  • CHU Nantes - Hôtel Dieu
    Nantes, 44093, France
  • Centre Odeon
    Paris, 75006, France
  • Hopital Lariboisiere
    Paris, 75010, France
  • Centre Ophtalmologique
    Paris, 75015, France
  • Centres Ophtalmologique St Exupéry
    Saint-Cyr-sur-Loire, 37540, France
  • Universitätsklinikum Köln
    Cologne, 50937, Germany
  • Universitätkslinikum Düsseldorf, Augenklinik
    Düsseldorf, 40225, Germany
  • Augenabteilung am St. Franziskus-Hospital
    Münster, 48145, Germany
  • Universitätsklinikum Münster
    Münster, 48149, Germany
  • The University of Hong Kong
    Hong Kong, Hong Kong
  • Hong Kong Eye Hospital
    Mong Kok, Hong Kong
  • Bajcsy-Zsilinszky Hospital
    Budapest, 1106, Hungary
  • Magyar Honvedseg Egeszsegugyi Kozpont
    Budapest, 1134, Hungary
  • Szegedi Tudományegyetem ÁOK
    Szeged, 6720, Hungary
  • Fondazione Ptv Policlinico Tor Vergata Di Roma
    Rome, Lazio 00133, Italy
  • UNIVERSITA' DEGLI STUDI DI GENOVA - Di.N.O.G.
    Genoa, Liguria 16132, Italy

Showing the first 100 of 137 sites across 21 countries. Choose a country and city above to see the rest.

09

References and documents

Publications

  • Khanani AM, Kotecha A, Chang A, Chen SJ, Chen Y, Guymer R, Heier JS, Holz FG, Iida T, Ives JA, Lim JI, Lin H, Michels S, Quezada Ruiz C, Schmidt-Erfurth U, Silverman D, Singh R, Swaminathan B, Willis JR, Tadayoni R; TENAYA and LUCERNE Investigators. TENAYA and LUCERNE: Two-Year Results from the Phase 3 Neovascular Age-Related Macular Degeneration Trials of Faricimab with Treat-and-Extend Dosing in Year 2. Ophthalmology. 2024 Aug;131(8):914-926. doi: 10.1016/j.ophtha.2024.02.014. Epub 2024 Feb 19. PubMed 38382813 ↗
  • Lim JI, Ambresin A, Avery RL, Chaikitmongkol V, Eter N, Gomi F, Khanani AM, London NJS, Harrell E, Margaron P, Patel S, Souverain A, Yang M, Lai TYY. Reduction in Pigment Epithelial Detachment Thickness with Faricimab versus Aflibercept 2 mg during Head-to-Head Dosing in TENAYA/LUCERNE. Ophthalmol Sci. 2026 Mar 10;6(5):101148. doi: 10.1016/j.xops.2026.101148. eCollection 2026 May. PubMed 42005909 ↗
  • Pitcher JD 3rd, Koh AHC, Tan CS, Vakharia P, Dagincourt N, Patel S, Yang M, Margaron P, Gallego-Pinazo R. Rapid Fluid Resolution and Durability With Faricimab in Neovascular Age-Related Macular Degeneration. JAMA Ophthalmol. 2026 Mar 1;144(3):269-272. doi: 10.1001/jamaophthalmol.2025.6365. PubMed 41712218 ↗
  • Takahashi K, Cheung CMG, Iida T, Lai TYY, Ohji M, Yanagi Y, Kawano M, Ohsawa S, Suzuki T, Kotecha A, Lin H, Patel V, Swaminathan B, Lee WK; TENAYA, LUCERNE Investigators. Efficacy, durability, and safety of faricimab in patients from Asian countries with neovascular age-related macular degeneration: 1-Year subgroup analysis of the TENAYA and LUCERNE trials. Graefes Arch Clin Exp Ophthalmol. 2023 Nov;261(11):3125-3137. doi: 10.1007/s00417-023-06071-8. Epub 2023 Jun 9. PubMed 37294433 ↗
  • Khanani AM, Guymer RH, Basu K, Boston H, Heier JS, Korobelnik JF, Kotecha A, Lin H, Silverman D, Swaminathan B, Willis JR, Yoon YH, Quezada-Ruiz C. TENAYA and LUCERNE: Rationale and Design for the Phase 3 Clinical Trials of Faricimab for Neovascular Age-Related Macular Degeneration. Ophthalmol Sci. 2021 Nov 17;1(4):100076. doi: 10.1016/j.xops.2021.100076. eCollection 2021 Dec. PubMed 36246941 ↗
  • Heier JS, Khanani AM, Quezada Ruiz C, Basu K, Ferrone PJ, Brittain C, Figueroa MS, Lin H, Holz FG, Patel V, Lai TYY, Silverman D, Regillo C, Swaminathan B, Viola F, Cheung CMG, Wong TY; TENAYA and LUCERNE Investigators. Efficacy, durability, and safety of intravitreal faricimab up to every 16 weeks for neovascular age-related macular degeneration (TENAYA and LUCERNE): two randomised, double-masked, phase 3, non-inferiority trials. Lancet. 2022 Feb 19;399(10326):729-740. doi: 10.1016/S0140-6736(22)00010-1. Epub 2022 Jan 24. PubMed 35085502 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — For eligible studies, qualified researchers may request access to individual patient level clinical data. See Roche's commitment to transparency of clinical study information here: https://go.roche.com/data_sharing

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Mar 2019 to primary completion in Oct 2020, 18 months.

Results were first posted in May 2022, 1 year 6 months after primary completion. A results delay was requested in Sep 2021.

Of 16 phase 3 interventional studies under Wet Macular Degeneration, half reached primary completion within 23 months of starting (the median), counting those still running; a quarter within 18 and three quarters within 50. This study's 18 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 29, 2019
First posted
Jan 30, 2019
StartActual
Mar 11, 2019
Primary completionActual
Oct 5, 2020
CompletionActual
Jan 7, 2022
Results delay requested
Sep 1, 2021
Results first posted
May 4, 2022
Last update
Jul 11, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 11, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03823300
Lead sponsor
Hoffmann-La Roche
Responsible party
Sponsor
First posted
Jan 30, 2019
Start date
Mar 11, 2019
Primary completion
Oct 5, 2020
Completion
Jan 7, 2022
Results posted
May 4, 2022
Last update
Jul 11, 2025

Study contacts

Clinical Trials
study director · Hoffmann-La Roche

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Faricimab

Start the discussion